

# FcγR-mediated SARS-CoV-2 infection of monocytes activates inflammation

<https://doi.org/10.1038/s41586-022-04702-4>

Received: 22 January 2021

Accepted: 29 March 2022

Published online: 6 April 2022

 Check for updates

Caroline Junqueira<sup>1,2,3,16</sup>✉, Ângela Crespo<sup>1,2,16</sup>, Shahin Ranjbar<sup>1,4,16</sup>, Luna B. de Lacerda<sup>1,2,3</sup>, Mercedes Lewandrowski<sup>1,2</sup>, Jacob Ingber<sup>1,2</sup>, Blair Parry<sup>5</sup>, Sagi Ravid<sup>1,2</sup>, Sarah Clark<sup>6</sup>, Marie Rose Schrimpf<sup>1,2</sup>, Felicia Ho<sup>1,2</sup>, Caroline Beakes<sup>5</sup>, Justin Margolin<sup>5</sup>, Nicole Russell<sup>5</sup>, Kyle Kays<sup>5</sup>, Julie Boucau<sup>7</sup>, Upasana Das Adhikari<sup>7</sup>, Setu M. Vora<sup>1,8</sup>, Valerie Leger<sup>9</sup>, Lee Gehrke<sup>6,9</sup>, Lauren A. Henderson<sup>2,10</sup>, Erin Janssen<sup>2,10</sup>, Douglas Kwon<sup>7</sup>, Chris Sander<sup>11</sup>, Jonathan Abraham<sup>6</sup>, Marcia B. Goldberg<sup>6,12</sup>, Hao Wu<sup>1,2,9</sup>, Gautam Mehta<sup>13,14</sup>, Steven Bell<sup>15</sup>, Anne E. Goldfeld<sup>1,4</sup>, Michael R. Filbin<sup>5,12</sup>✉ & Judy Lieberman<sup>1,2</sup>✉

SARS-CoV-2 can cause acute respiratory distress and death in some patients<sup>1</sup>. Although severe COVID-19 is linked to substantial inflammation, how SARS-CoV-2 triggers inflammation is not clear<sup>2</sup>. Monocytes and macrophages are sentinel cells that sense invasive infection to form inflammasomes that activate caspase-1 and gasdermin D, leading to inflammatory death (pyroptosis) and the release of potent inflammatory mediators<sup>3</sup>. Here we show that about 6% of blood monocytes of patients with COVID-19 are infected with SARS-CoV-2. Monocyte infection depends on the uptake of antibody-opsonized virus by Fcγ receptors. The plasma of vaccine recipients does not promote antibody-dependent monocyte infection. SARS-CoV-2 begins to replicate in monocytes, but infection is aborted, and infectious virus is not detected in the supernatants of cultures of infected monocytes. Instead, infected cells undergo pyroptosis mediated by activation of NLRP3 and AIM2 inflammasomes, caspase-1 and gasdermin D. Moreover, tissue-resident macrophages, but not infected epithelial and endothelial cells, from lung autopsies from patients with COVID-19 have activated inflammasomes. Taken together, these findings suggest that antibody-mediated SARS-CoV-2 uptake by monocytes and macrophages triggers inflammatory cell death that aborts the production of infectious virus but causes systemic inflammation that contributes to COVID-19 pathogenesis.


SARS-CoV-2 causes severe COVID-19 marked by acute respiratory distress that can progress to multiorgan failure and death in older individuals and patients with comorbidities<sup>1</sup>. Increased chronic inflammation is associated with ageing (inflammaging) and the comorbidities linked to severe disease<sup>4</sup>, and severe disease is linked to signs of inflammation<sup>2</sup>. When myeloid cells sense invasive infection, they activate inflammasomes to sound an innate immune alarm<sup>3</sup>. Inflammasome activation is required to process and release interleukin-1 (IL-1)-family cytokines, arguably the most potent inflammatory mediators<sup>5</sup>. However, activation of NF-κB, the TNF receptor superfamily and T helper 17 (T<sub>H</sub>17) cell cytokines can also cause severe inflammation. When inflammasomes sense infection, they recruit the ASC adaptor and assemble into large complexes that recruit and activate caspase-1, which in turn processes IL-1 pro-cytokines and the pore-forming gasdermin D (GSDMD) to

disrupt the cell membrane, leading to cell death and cytokine release<sup>3</sup>. Pyroptotic cell membrane rupture releases cytokines, chemokines and other alarmins that recruit immune cells to infection sites. LDH release is pathognomonic for pyroptosis and other forms of necrotic cell death<sup>3</sup> and elevated LDH is one of the best correlates of severe COVID-19<sup>6</sup>.

## COVID-19 blood shows signs of pyroptosis

As inflammasome activation is a major mediator of inflammation<sup>7</sup>, we examined the blood of patients infected with SARS-CoV-2 for inflammasome activation and pyroptosis. Freshly isolated mononuclear cells from 19 healthy donor individuals (HDs) and 22 patients with COVID-19 in the emergency department were stained for haematopoietic cell markers; with a small fixable dye (Zombie Yellow) that enters cells with

<sup>1</sup>Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA, USA. <sup>2</sup>Department of Pediatrics, Harvard Medical School, Boston, MA, USA. <sup>3</sup>Instituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Brazil. <sup>4</sup>Department of Medicine, Harvard Medical School, Boston, MA, USA. <sup>5</sup>Emergency Medicine, Institute for Patient Care, Massachusetts General Hospital, Boston, MA, USA. <sup>6</sup>Department of Microbiology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA. <sup>7</sup>Ragon Institute, Massachusetts General Hospital, Massachusetts Institute of Technology, Harvard Medical School, Cambridge, MA, USA. <sup>8</sup>Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. <sup>9</sup>Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, USA. <sup>10</sup>Division of Immunology, Boston Children's Hospital, Boston, MA, USA. <sup>11</sup>cBio Center, Dana-Farber Cancer Institute and Department of Cell Biology, Harvard Medical School, Boston, MA, USA. <sup>12</sup>Center for Bacterial Pathogenesis, Department of Medicine, Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA. <sup>13</sup>Institute for Liver and Digestive Health, University College London, London, UK. <sup>14</sup>Institute of Hepatology, Foundation for Liver Research, London, UK. <sup>15</sup>Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK. <sup>16</sup>These authors contributed equally: Caroline Junqueira, Ângela Crespo, Shahin Ranjbar. ✉e-mail: caroline.junqueira@childrens.harvard.edu; mfilbin@mgh.harvard.edu; judy.lieberman@childrens.harvard.edu




**Fig. 1 | Monocytes of patients with COVID-19 undergo pyroptosis.**

**a, b**, Representative flow cytometry plots (**a**) and the percentage of lymphocyte subset and monocyte (Mo) staining for annexin V only or Zombie dye (**b**) in fresh blood from HDs ( $n = 16$ ) and patients with COVID-19 ( $n = 22$ ). NK, natural killer cells. **c**, The frequency of monocyte subsets (classical, CD14<sup>high</sup>CD16<sup>-</sup>; intermediate, CD14<sup>high</sup>CD16<sup>+</sup>; and non-classical, CD14<sup>low</sup>CD16<sup>+</sup>) in freshly isolated blood from HDs ( $n = 11$ ) and patients with COVID-19 ( $n = 12$ ). **d, e**, Imaging flow cytometry analysis of SARS-CoV-2 infection in monocyte subsets of patients with COVID-19 ( $n = 12$ ). Monocytes from patients with COVID-19 were enriched by negative selection and stained for CD14, CD16 and SARS-CoV-2 N. **d**, Representative dot plots of monocyte subsets gated on all monocytes (left) or N<sup>+</sup> monocytes. **e**, Representative images of imaging flow cytometry (left) and quantification of infection (N<sup>+</sup>) in the monocyte subsets (right). BF, bright field. Scale bar, 7  $\mu\text{m}$ . **f**, The concentration of anti-spike RBD IgG in the plasma of HDs ( $n = 20$ ), non-COVID-19 patients (with COVID-19-like symptoms but PCR negative for SARS-CoV-2;  $n = 5$ ) and patients with COVID-19 ( $n = 68$ ) at presentation. **g**, The concentration of pyroptosis biomarkers and

cytokines in HD and COVID-19 plasma. GSDMD ( $n = 12$  (HD),  $n = 29$  (COVID-19)); LDH activity ( $n = 10$  (HD),  $n = 36$  (COVID-19)); IL-1 $\beta$  ( $n = 8$  (HD),  $n = 41$  (COVID-19)); IL-1RA and IL-18 ( $n = 6$  (HD),  $n = 10$  (COVID-19)). A description of the samples is provided in Supplementary Table 1. OD<sub>490</sub>, optical density at 490 nm. **h**, Plasma pyroptosis biomarkers at presentation (day 0) and during hospitalization (day 3 and 7) in patients with COVID-19 with mild ( $n = 12$ ), moderate ( $n = 16$ ) and severe ( $n = 32$ ) COVID-19 Acuity scores (the samples are described in Supplementary Table 2). Left, individual patient data. Right, grouped data. For **b, c, e, f, h**, data are mean  $\pm$  s.e.m. The plots in **g** show the median (centre line), the interquartile range between the 25th and 75th percentiles (box), and the 25th percentile value - 1.5 $\times$  the interquartile range (lower whisker) and the 75th percentile value + 1.5 $\times$  the interquartile range (upper whisker). Statistical analysis was performed using two-tailed nonparametric unpaired *t*-tests (**b, c**), one-way analysis of variance (ANOVA) with Tukey multiple-comparisons test (**e, f**), two-tailed nonparametric unpaired *t*-tests (**g**) and two-way ANOVA with Tukey multiple-comparisons test (**h**); \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , \*\*\*\* $P < 0.0001$ .

damaged plasma membranes; and for annexin V, an indicator of programmed cell death (Fig. 1a, b, Extended Data Fig. 1a and Supplementary Table 1). Annexin V<sup>+</sup>Zombie<sup>-</sup> apoptotic cells did not increase in any subpopulation in samples from patients with COVID-19. However, around 6% of monocytes of patients with COVID-19 on average took up Zombie dye, a sign of membrane damage consistent with pyroptosis. None of the lymphocyte subsets in samples from patients with COVID-19 showed increased pyroptosis. Monocyte flow cytometry analysis indicated that

there was a reduced frequency of classical monocytes (CD14<sup>high</sup>CD16<sup>-</sup>) in 15 patients with COVID-19 compared with 13 HDs, whereas intermediate monocytes (CD14<sup>high</sup>CD16<sup>+</sup>) were significantly increased, but there was no change in the non-classical subset (CD14<sup>low</sup>CD16<sup>+</sup>) (Fig. 1c and Extended Data Fig. 1b). Many intermediate (about 60%) and non-classical (about 40%), but none of the more abundant classical, monocytes had taken up SARS-CoV-2 virus as they stained for nucleocapsid (N) (Fig. 1d, e). As only monocytes that expressed CD16—an




**Fig. 2 | Monocytes of patients with COVID-19 have activated inflammasomes, caspase-1 and GSDMD.** Monocytes from HDs, non-COVID-19 patients or patients with COVID-19 at the time of presentation were analysed by imaging flow cytometry for ASC, GSDMD, caspase-1 activation (FLICA) and/or Zombie dye uptake. **a–c**, The percentage of monocytes with activated ASC (**a**) or caspase-1 (**b**) ( $n = 8$  (HD),  $n = 5$  (non-COVID-19),  $n = 10$  (COVID-19)) or colocalized ASC/caspase-1 specks (**c**) ( $n = 8$  (HD),  $n = 4$  (non-COVID-19),  $n = 8$  (COVID-19)) (**c**). Representative images (top) and quantification of all samples (bottom) are shown. **d**, The percentage of ASC-speck-containing monocytes with colocalized activated caspase-1, NLRP3, AIM2 or pyrin specks.  $n = 6$ . **e, f**, Representative images of ASC (**e**) or Zombie dye (**f**) and GSDMD co-stained monocytes.  $n = 4$  independent experiments. **g**, Lysates of purified monocytes of HDs and patients with COVID-19, and of LPS- and nigericin-treated monocytes of HDs (+) probed

with a monoclonal antibody that recognizes full length GSDMD (GSDMD-FL) and the C-terminal of GSDMD (GSDMD-CT) (top),  $\beta$ -actin (middle) and COX-IV (bottom). Representative of  $n = 4$  independent experiments. **h, i**, Representative images of ASC co-staining with NLRP3 (left;  $n = 5$  (HD),  $n = 4$  (non-COVID-19),  $n = 6$  (COVID-19)), AIM2 (middle;  $n = 4$  (HD),  $n = 3$  (non-COVID-19),  $n = 4$  (COVID-19)) and pyrin (right;  $n = 4$  (HD),  $n = 4$  (non-COVID-19),  $n = 5$  (COVID-19)) (**h**), and quantification of monocytes showing ASC specks colocalized with the indicated inflammasomes (**i**). **j**, Representative images of co-staining of ASC, NLRP3 and AIM2.  $n = 3$  independent experiments. For **a–c, e, f, h, j**, scale bars, 7  $\mu$ m. For **a–d, i**, data are mean  $\pm$  s.e.m. Statistical analysis was performed using one-way ANOVA with Tukey multiple-comparisons test (**a–d**) and two-way ANOVA with Tukey multiple-comparisons test (**i**); \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , \*\*\*\* $P < 0.0001$ .

important mediator of antibody-dependent phagocytosis—took up virus, anti-spike RBD IgG plasma titres were measured in plasma samples of 64 patients with COVID-19 that were obtained at presentation at the emergency department, 20 HDs and 5 patients who presented with COVID-19-like symptoms but were SARS-CoV-2 PCR negative (hereafter, non-COVID-19 patients) (Fig. 1f). Most patients with COVID-19, but not HDs or non-COVID-19 controls, had elevated anti-spike RBD IgG, suggesting that they had been infected for approximately a week<sup>8</sup>. Plasma samples from patients with COVID-19 with diverse disease outcomes and HDs were compared for pyroptosis-specific markers

(GSDMD, IL-1 $\beta$ , IL-1RA, IL-18 and LDH activity) (Fig. 1g), inflammatory markers not specific for pyroptosis (inflammatory cytokines IL-6, TNF and IL-17/17A; growth factors IL-7 and G-CSF; and chemokines CCL7, CXCL9 and CXCL10) and interferons (IFN $\beta$  and IFN $\gamma$ ). Consistent with published data<sup>9,10</sup>, all inflammation markers that are not specific for pyroptosis were significantly elevated in the plasma of patients with COVID-19 (except for IL-17/17A) and IFNs were not detected above the baseline (data not shown). All pyroptosis markers were significantly elevated in the plasma of patients with COVID-19 compared with HDs. Although significantly higher in samples from patients with COVID-19,



**Fig. 3 | SARS-CoV-2-infected monocytes and lung macrophages have activated inflammasomes.** **a–h**, Monocytes of HDs and patients with COVID-19 were stained for SARS-CoV-2 N ( $n = 5$ ) (**a–d**) or dsRNA (anti-J2 antibodies) ( $n = 4$ ) (**e–h**) and ASC. **a, e**, Representative imaging flow cytometry images. **b, f**, Quantification of infected cells on the basis of N (**b**) or J2 (**f**) staining. **c, g**, Uninfected or infected cells that showed ASC specks. **d, h**, The percentage of cells with or without ASC specks that were infected. For **a, e**, scale bars, 7  $\mu\text{m}$ . **i–k**, Lung autopsies from five patients with COVID-19 (the samples are described in Supplementary Table 3) and three control individuals who have experienced trauma were stained for N (green), ASC (red) and CD14 (magenta), and with DAPI (blue). **i**, Digital scanner images of a representative patient who experienced trauma (left) and a patient with COVID-19 (middle), showing a magnified image of representative infected

CD14<sup>+</sup> (top) and CD14<sup>-</sup> (bottom) cells from the lungs of the patient with COVID-19 (right). Scale bars, 50  $\mu\text{m}$  (left), 100  $\mu\text{m}$  (middle). **j, k**, Representative confocal microscopy COVID-19 lung images of infected CD14<sup>+</sup> (**j**) and CD14<sup>-</sup> (**k**) cells (left). Right, quantification of CD14<sup>+</sup> (**j**) and CD14<sup>-</sup> (**k**) cells that are N positive and/or have ASC specks in the lungs of patients with COVID-19 ( $n = 5$ ) and control individuals ( $n = 3$ ). In **k**, representative images of CD14<sup>+</sup> N<sup>+</sup> cells (left) were co-stained for ASC and E-cadherin, an epithelial marker (top), or CD31, an endothelial marker (bottom). For **j, k**, scale bars, 7  $\mu\text{m}$ . For **b–d, f–h, j, k**, data are mean  $\pm$  s.e.m. Statistical analysis was performed using two-tailed nonparametric unpaired *t*-tests (Mann–Whitney *U*-tests) (**b–d, f–h**) and two-way ANOVA with Tukey multiple-comparisons test (**j, k**); \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , \*\*\*\* $P < 0.0001$ .

plasma IL-1 $\beta$  was low, which was not surprising as it is rapidly cleared and is usually not detected even in patients with pyroptosis-mediated diseases. However, its antagonist IL-1RA, used as a surrogate<sup>5</sup>, was greatly increased in samples from patients with COVID-19. Note that IL-1 cytokines and pyroptosis potentially activate the other elevated inflammation markers<sup>11</sup>.


To determine whether pyroptosis biomarkers correlate with COVID-19 disease severity, plasma from 10 HDs and 60 patients with COVID-19 was analysed for GSDMD, LDH, IL-1RA and IL-18 at presentation and on days 3 and 7 for hospitalized patients (Fig. 1h and Supplementary Table 2). The patients were grouped into mild, moderate or severe

disease using the MGH COVID Acuity scale<sup>12</sup>. Plasma GSDMD, LDH, IL-1RA and IL-18 were all elevated in the samples from patients with severe disease compared with those with mild or moderate disease, but the increase in GSDMD was not significant. Taken together, these results suggest ongoing pyroptosis in COVID-19 blood that was more prominent in severe disease.

### Monocytes have activated inflammasomes

These data suggested that monocytes in patients with COVID-19 might die of pyroptosis and release inflammatory cytokines to contribute





**Fig. 4 | HD monocytes take up antibody-opsioned SARS-CoV-2 through an Fc $\gamma$ R but viral replication is aborted.** **a–d**, HD monocytes ( $n = 3$ ) were primed (black bars) or not (white bars) with LPS, infected with icSARS-CoV-2-mNG and stained 48 h later for N and ASC. Virus was preincubated with IgG1 control mAb114, non-neutralizing anti-spike (C1A-H12) or neutralizing anti-RBD (C1A-B12), or with pooled plasma from patients with COVID-19, and these were retained throughout culture. **a**, Representative imaging flow cytometry images of uninfected (top), N<sup>+</sup>NG<sup>-</sup> (middle) or N<sup>+</sup>NG<sup>+</sup> (bottom) monocytes. Scale bar, 7  $\mu$ m. **b–d**, Quantification of the percentage of ASC speck<sup>+</sup> (**b**) or N<sup>+</sup> (**c**) monocytes, and of N<sup>+</sup> monocytes with ASC specks (**d**).  $n = 3$ . **e–i**, LPS-activated HD monocytes were infected with icSARS-CoV-2-mNG preincubated with pooled COVID-19 plasma, depleted or not depleted of immunoglobulins using protein A/G beads ( $n = 3$ ; **e**), or preincubated with pooled plasma from HDs, recipients of a COVID-19 mRNA vaccine, non-COVID-19 patients or patients with COVID-19 with mild and/or severe disease ( $n = 3$ ; **f**, **g**); or with purified IgG from HDs ( $n = 3$ ), pooled from patients with COVID-19 of mixed severity ( $n = 3$ ) or patients with COVID-19 with low (about 8%) or high (about 30%) afucosylated (Afucos.) anti-spike IgG ( $n = 11$ ) (**h**, **i**). Infection was quantified by N staining (**f**, **h**) or NG fluorescence (**e**, **g**, **i**). **j–m**, LPS-treated HD monocytes were infected

with icSARS-CoV-2-mNG, preincubated with pooled plasma from patients with COVID-19, depleted or not depleted of IgG or IgA as indicated, in the presence of the indicated blocking or isotype control (Iso) antibodies ( $n = 3$ ; **j**, **k**) or antiviral drugs (**l** (10  $\mu$ M remdesivir), **m**), and infection was assessed 48 h later by NG fluorescence. The statistical analysis in **m** compared drug with no drug. **n**, **o**, RT-qPCR analysis of genomic SARS-CoV-2/RNA (**n**) and sgRNA (**o**, left) in uninfected or infected HD monocytes ( $n = 3$ ), normalized to *ACTB* mRNA. Infected HEK293T cells were used as a positive control ( $n = 3$ ). Agarose gel electrophoresis of ethidium-bromide-stained RT-qPCR-amplified sgRNA is shown (**o**, right). The approximately 1,600-bp band in the samples from patients with COVID-19 was sequenced and confirmed to be N sgRNA. **p**, SARS-CoV-2 plaque-forming units (PFU) in culture supernatants of infected monocytes (Mono) or Vero E6 cells collected at the indicated hours post-infection (h.p.i.). For **b–p**, data are mean  $\pm$  s.e.m. Statistical analysis was performed using two-way ANOVA with Sidak multiple-comparisons test (**b–d**), two-tailed nonparametric unpaired *t*-tests (**e**) and one-way ANOVA with Tukey multiple-comparisons test (**f–p**); \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , \*\*\*\* $P < 0.0001$ . Data are representative of  $n = 3$  replicate experiments.

to poor outcome. Not much is known about how viruses interact with the 27 potential human canonical inflammasome sensors<sup>3</sup>. The NLRP3 inflammasome, which detects K<sup>+</sup> efflux generated by a variety of stimuli, could be activated by specific viral proteins<sup>13,14</sup>. Three SARS-CoV-2 proteins—Orf3a, Orf8 and envelope (E)—are thought to be ‘viroporins’ (ion channels) that potentially activate K<sup>+</sup> efflux, as previously described for SARS-CoV<sup>15</sup>. Orf3 and Orf8 are encoded only by pathogenic human coronaviruses. Interestingly, bats, which are the natural hosts of SARS-CoV and SARS-CoV-2, have a dampened NLRP3 response to multiple viruses, including MERS-CoV, which might explain their toleration of these infections despite high viral loads<sup>16</sup>. To examine whether monocytes of patients with COVID-19 undergo pyroptosis, freshly isolated, enriched monocytes from HDs, patients with COVID-19 of mixed disease severity

(Supplementary Table 1) and non-COVID-19 patients were analysed using imaging flow cytometry for the expression and intracellular distribution of the common inflammasome adaptor ASC, activated caspase-1 (using the fluorochrome-labelled inhibitor of caspases assay (FLICA)) and GSDMD. Activated canonical inflammasomes form large micrometre-sized inflammasome–ASC–caspase-1 specks<sup>3</sup>. About 4% of monocytes from patients with COVID-19, 1% of monocytes from non-COVID-19 patients, but no monocytes from HDs, had caspase-1 and ASC specks (Fig. 2a–c and Extended Data Fig. 2a, b). These results suggest that other causes of respiratory distress activate monocyte inflammasomes, but activation is more extensive in SARS-CoV-2 infection. Most cells with ASC specks (about 80%) from patients with COVID-19 also had colocalized caspase-1 specks (Fig. 2d).

COVID-19 monocytes with ASC specks showed ballooning plasma membranes, GSDMD redistribution from the cytoplasm to cell membrane puncta and Zombie dye uptake, consistent with GSDMD pore formation and pyroptosis, but cells without ASC specks did not (Fig. 2e, f and Extended Data Fig. 2b, e). Most Zombie<sup>+</sup> cells had ASC specks (62 ± 9%), suggesting that most COVID-19 monocyte death is due to inflammasome activation. However, only 28 ± 5% of cells with ASC specks had taken up Zombie dye. This difference could be because cell membrane permeabilization is delayed after ASC activation and dying cells with damaged membranes are rapidly removed from the blood. Immunoblots of monocyte lysates of HDs and patients with COVID-19 were probed for full-length GSDMD (GSDMD-FL) and its C-terminal fragment (GSDMD-CT) and housekeeping proteins, β-actin and COX-IV (Fig. 2g and Extended Data Fig. 2g). During pyroptosis, cleaved GSDMD and actin are released and the actin cytoskeleton disintegrates, whereas membrane-bound proteins, such as COX-IV, are mostly retained<sup>3,17</sup>. GSDMD-FL was detected in all of the HD samples, but in only 1 out of 3 samples from patients with COVID-19. GSDMD-CT was detected in monocytes of patients with COVID-19 and the positive control (LPS + nigericin-treated HD monocytes). Although COX-IV was detected in all of the samples, full-length β-actin was not detected in one COVID-19 sample, but β-actin fragments were detected in all of the samples from patients with COVID-19 and in nigericin-activated HD monocytes. Thus, monocytes of patients with COVID-19 are undergoing pyroptosis.

To identify the activated inflammasome, monocytes of HDs and patients with COVID-19 were co-stained for ASC and three canonical inflammasomes (NLRP3, AIM2 (activated by cytoplasmic DNA) and pyrin (activated by bacterial toxins))<sup>14</sup> (Fig. 2d, h–j and Extended Data Fig. 2c–f). In monocytes of patients with COVID-19, ASC specks colocalized with NLRP3 and AIM2, but there were no pyrin specks. AIM2 activation was unexpected, although AIM2 is activated by RNA viruses in rare cases by an unclear mechanism<sup>18</sup>. AIM2 might sense host mitochondrial DNA as mitochondrial membranes are damaged during pyroptosis<sup>19</sup>. Almost all ASC-speck-positive monocytes had colocalized NLRP3 and AIM2 specks (Fig. 2d), and ASC, NLRP3 and AIM2 colocalized (Fig. 2j). We did not expect to find more than one inflammasome stimulated in the same cell, although colocalization of two distinct inflammasomes has been reported<sup>20</sup>. Confocal microscopy confirmed ASC, caspase-1, NLRP3 and AIM2 colocalization in inflammasomes selectively in COVID-19 monocytes (Extended Data Fig. 2f). These data showing inflammasome specks and GSDMD membrane localization and cleavage, together with the detection of dying annexin V-Zombie<sup>+</sup> monocytes and plasma GSDMD and IL-1 cytokines (Fig. 1), indicate that COVID-19 monocytes die of pyroptosis.

### Monocyte infection triggers pyroptosis

We next examined what activates inflammasomes in COVID-19 monocytes. As inflammasomes sense invasive infection, monocyte infection might be the trigger. A few reports suggest that monocytes<sup>10,21</sup> and macrophages can be infected by SARS-CoV-2, and we detected nucleocapsid in patient monocytes (Fig. 1d, e). However, monocytes do not express ACE2, the viral entry receptor<sup>22</sup>. Indeed, ACE2 was undetected or barely detected by flow cytometry and quantitative PCR with reverse transcription (RT-qPCR) analysis of monocytes of patients with COVID-19 and HDs (Extended Data Fig. 3a, b). Monocytes of HDs and patients with COVID-19 expressed similar levels of CD147 (also known as basigin and EMMPRIN), which is reported to bind to the SARS-CoV-2 spike protein and facilitate viral uptake, although this finding is controversial<sup>23–25</sup> (Extended Data Fig. 3c, d). Monocytes express three Fcγ receptors—CD64 (FcγRI) and CD32 (FcγRII), which is expressed on most blood monocytes, and CD16 (FcγRIIIa), which is expressed on a small minority of blood monocytes (around 10% in HDs)<sup>26,27</sup>—that are increased in COVID-19<sup>9</sup>. These receptors could recognize antibody-opsonized

virions and mediate uptake through antibody-dependent phagocytosis<sup>28</sup>. Anti-SARS-CoV-2 spike antibodies are detected early in SARS-CoV-2 infection, about when patients develop inflammatory symptoms<sup>8,29</sup>, as in our cohort (Fig. 1f). To examine whether monocytes of patients with COVID-19 are infected, we co-stained monocytes of HDs and patients with COVID-19 for nucleocapsid (N) (Fig. 3a–d) or double-stranded RNA (dsRNA) (anti-J2 antibodies) (Fig. 3e–h) and ASC. N staining indicates virus internalization, but J2 staining indicates active infection<sup>30</sup>. Monocytes of HDs did not stain for N, dsRNA or ASC. About 10% of monocytes from patients with COVID-19 stained for N or dsRNA (Fig. 3b, f) and around 95% of N<sup>+</sup> monocytes were also J2 positive, indicating viral replication. Almost all infected cells showed ASC specks (Fig. 3c, g) and all ASC-speck-positive cells were infected (Fig. 3d, h). Thus, SARS-CoV-2 monocyte infection activates inflammasomes and pyroptosis.

### Lung macrophages have inflammasome specks

As the respiratory tract is the main infection site, we next assessed whether macrophages in lung autopsies were infected with SARS-CoV-2 and had active inflammasomes. Fixed lung slides from five individuals with SARS-CoV-2 infection (Supplementary Table 3) and three uninfected individuals who have experienced trauma were co-stained for CD14, ASC, N and DAPI (Fig 3i–k). In the lungs of patients with COVID-19, 15.1 ± 2.9% of CD14<sup>+</sup> cells and 8.3 ± 4.2% of CD14<sup>+</sup> cells stained for N, but N was not detected in the unaffected individuals who have experienced trauma (Fig 3i–k). As expected, both E-cadherin<sup>+</sup> epithelial and CD31<sup>+</sup> endothelial CD14<sup>+</sup> cells stained for N (Fig 3k). However, ASC specks were detected only in CD14<sup>+</sup>, but not in CD14<sup>−</sup>, COVID-19 lung cells, indicating that tissue-resident macrophages have activated ASC-containing inflammasomes, but infected lung epithelial and endothelial cells do not. Most CD14<sup>+</sup>N<sup>+</sup> cells had ASC specks (Fig. 3j). ASC specks were not seen in control autopsies. About a quarter of CD14<sup>+</sup> lung cells had ASC specks, although only approximately 8% were N positive, suggesting that danger-associated molecular patterns, released from infected or otherwise damaged lung cells, may have activated inflammasomes in uninfected macrophages.

### CD16 mediates infection of opsonized virus

To confirm that monocytes can be infected, monocytes of HDs were infected with an engineered infectious clone (icSARS-CoV-2-mNG) encoding a Neon Green (NG) fluorescent reporter of viral replication<sup>31</sup>. Monocytes, primed or not with LPS, were infected (multiplicity of infection of 1) with reporter virus preincubated with IgG1 isotype control antibodies (mAb114), anti-spike monoclonal antibodies (non-neutralizing (C1A-H12) or neutralizing (C1A-B12))<sup>32</sup> or pooled plasma (heat-inactivated or not) from HDs or patients with COVID-19. Antibodies and plasma were also present during culture. After 48 h, monocytes were analysed for N, dsRNA and ASC by imaging flow cytometry (Fig. 4a–g and Extended Data Fig. 4). Without LPS, anti-spike antibodies or COVID-19 pooled plasma, few monocytes of HDs took up or replicated the virus, but infection increased significantly in the presence of anti-spike monoclonal antibodies or plasma from patients with COVID-19. Antibody-neutralizing activity and plasma heat-inactivation did not affect infection (Extended Data Fig. 4a–e), suggesting that complement was not involved. IgG-depletion of plasma from patients with COVID-19 nearly abrogated viral infection, assessed by NG fluorescence, but IgA depletion had no effect on infection (Fig. 4e, j, k). These results suggest that infection is mediated by virus opsonized by anti-spike antibodies. Nonetheless, N-, J2- and NG-positive monocytes were detected at low levels after infection of HD monocytes with virus preincubated with isotype control monoclonal antibodies or with HD plasma, suggesting possible inefficient anti-SARS-Cov-2-antibody-independent monocyte infection. The highest in vitro infection rate was around 3% in HD monocytes that were pretreated with LPS and incubated

with patient plasma. N and J2 staining were comparable, with a low background of around 0.1% in uninfected samples; fewer cells were NG fluorescent (about half as many) and there was no background NG fluorescence. More J2<sup>+</sup> or N<sup>+</sup> cells in samples with the highest infection rates (treated with LPS and patient plasma or anti-spike antibodies) were also NG fluorescent, indicating viral replication (Extended Data Fig. 4e). NG may be detected less often than N or dsRNA because it is expressed late in the viral lifecycle and/or is more difficult to detect. ASC specks were barely detected in uninfected HD monocytes but increased with SARS-CoV-2 infection (Fig. 4c and Extended Data Fig. 4d). ASC-speck-positive cells increased when SARS-CoV-2 was preincubated with anti-spike antibodies and still more when preincubated with patient plasma. HD monocyte infection with the fluorescent molecular clone was similar to infection with the parental Washington (WA) strain or a Delta variant clinical isolate but, as expected, the molecular clone less efficiently infected A549-ACE2 cells compared with the WA strain or the more infectious Delta variant (Extended Data Fig. 4f, g). The similarity of HD monocyte infection for all three viruses suggested that monocyte viral entry might be ACE2-independent.

To assess whether disease severity or antibodies raised by vaccination increased monocyte virus uptake, LPS-activated monocytes were infected in the presence of pooled plasma from uninfected donors, mRNA vaccine recipients or patients with COVID-19 with mild or severe disease. Importantly, uninfected HD and post-vaccination plasma did not facilitate virus uptake or replication, even though plasma anti-RBD IgG was around twofold higher in HD vaccine recipients ( $6.5 \pm 1.1 \mu\text{g ml}^{-1}$ ) than in patients with COVID-19 ( $3.6 \pm 0.5 \mu\text{g ml}^{-1}$ ) (Fig. 4f, g). However, pooled plasma from non-COVID-19 patients slightly increased infection, but the increase was not significant, suggesting possible inefficient viral uptake by some non-COVID plasma component. Disease severity did not affect infection by the plasma of patients with COVID-19 as pooled mild and/or severe plasma similarly facilitated infection.

Patients with severe acute COVID-19 have increased antiviral IgGs that are afucosylated in their Fc region and bind better to CD16<sup>33–35</sup>. To test whether afucosylation affects HD monocyte infection, HD monocyte infection by virus preincubated with purified IgG from pooled plasma from HDs or patients with COVID-19, or from patients with COVID-19 with relatively low (about 8%) or high (about 30%) afucosylation (2 patients of each) was compared (Fig. 4h, i). As expected, purified HD plasma IgG did not lead to N staining or NG fluorescence, whereas IgG from pooled plasma from patients with COVID-19 did. Low afucosylated IgG did not significantly increase infection compared to HD IgG, but more highly afucosylated COVID-19 IgGs modestly, but significantly, increased N<sup>+</sup> cells. However, NG fluorescence did not increase significantly after adding either low- or high-afucosylated IgG from patients with COVID-19 compared to HD IgG, perhaps because this assay is less sensitive than N staining. Purified IgG enhanced HD monocyte infection less than patient plasma (compare Fig. 4l, m with Fig. 4f, g), suggesting that an Ig-independent plasma component might facilitate infection.

To identify the viral receptor on monocytes, purified HD monocytes were infected with the reporter virus in the presence of plasma of patients with COVID-19 that was or was not depleted of IgG or in the presence of blocking antibodies to potential monocyte receptors—ACE2, CD147 and the three monocyte FcγRs, CD16, CD32 and CD64 (Fig. 4j, k and Extended Data Fig. 5a, b). Blocking CD16 or CD64 or IgG depletion strongly inhibited infection, whereas blocking the other receptors had no significant effect. The combination of anti-CD16 and anti-CD64 blocking antibodies did not inhibit virus uptake more than either blocking antibody on its own. Thus, SARS-CoV-2 infection of monocytes is mostly mediated by CD16 and/or CD64 uptake of opsonized virus.

CD16 is also expressed on neutrophils and cytotoxic T and natural killer cells, which could be infected by a similar antibody-dependent mechanism. We did not observe increased cell death in patient lymphocytes (Fig. 1a) and therefore did not study them further. However,

neutrophils contribute to SARS-CoV-2 immunopathology and inflammation<sup>36</sup>. To determine whether neutrophils are infected, HD neutrophils and monocytes were infected side by side in the presence of COVID-19 plasma (Extended Data Fig. 5b, c). Infection of HD neutrophils was low compared with monocyte infection (around 0.2% versus almost 3% in monocytes) and not significantly increased above background. To assess whether neutrophils are infected *in vivo*, the frequency of *in vivo* neutrophil infection in samples from COVID-19 patients of mixed disease severity and HDs was assessed by N staining negatively selected, fresh blood neutrophils (Extended Data Fig. 5d). Infection was not detected in neutrophils of patients with COVID-19.

### SARS-CoV-2 monocyte infection is aborted

dsRNA and NG detection strongly suggested that monocytes replicate SARS-CoV-2. To confirm viral replication and further assess whether uptake is ACE2 mediated, HD monocytes were infected in the presence of plasma from patients with COVID-19 and the antiviral drugs remdesivir, an inhibitor of the viral RNA-dependent RNA polymerase, and camostat mesylate, an inhibitor of TMPRSS2, which primes the spike protein for ACE2-mediated entry<sup>37</sup> (Fig. 4l, m and Extended Data Fig. 5e–g). Monocyte infection, assessed by N or NG positivity, was unaffected by camostat, but significantly and comparably inhibited by Ig depletion or remdesivir, confirming antibody-dependent entry and viral replication. A lack of inhibition by camostat and anti-ACE2 antibodies suggests that ACE2 is unlikely to be a dominant receptor for viral entry into monocytes but does not rule out a small role in monocyte infection or a more prominent role in the infection of ACE2<sup>+</sup> macrophages. Early in viral replication, a series of positive-strand subgenomic RNAs (sgRNAs) is transcribed with a common leader sequence that specifically indicates viral replication<sup>16</sup>. RT-qPCR was used to detect SARS-CoV-2 genomic RNAs (gRNAs) and sgRNAs using primers targeting the N1 region of the *N* gene and the shared leader sequence and 3' UTR sequences of the sgRNAs, respectively. gRNA and sgRNA were detected only in SARS-CoV-2-infected HD monocytes (Fig. 4n, o). The most abundant amplified sgRNA fragment migrated on agarose gels at the size of the *N*sgRNA (1,560 nucleotides), and its identity was confirmed by sequencing.

Although multiple assays indicated monocytes begin viral replication, we next assessed whether infected monocytes produce infectious virus. Infectious SARS-CoV-2 is detected in plasma of patients with COVID-19 only with especially sensitive assays, and we did not detect infectious virus by plaque assay in plasma samples from nine patients with COVID-19. Although infected HD monocyte culture supernatants formed plaques in Vero cells when culture supernatants were collected immediately after infection (probably detecting input virus), no infectious virus was detected when culture supernatants were collected 48 h after infection (Fig. 4p). By contrast, plaques were easily detected in culture supernatants from infected Vero cells collected at 48 h after infection. Thus, monocyte infection did not produce infectious virus.

### Discussion

Here we show antibody-opsonized SARS-CoV-2 infects and replicates in blood monocytes and lung macrophages. About 10% of monocytes and 8% of lung macrophages in patients with COVID-19 were SARS-CoV-2-infected. We found a one-to-one correspondence between monocyte infection and inflammasome caspase-1 activation and pyroptosis. Most dying monocytes in the blood of patients with COVID-19 had activated inflammasomes, suggesting that monocytes are dying of pyroptosis. This is a large number, considering that dying cells are rapidly eliminated *in vivo*. It may be surprising that monocyte infection and cell death has not been widely recognized. However, this may be because (1) many COVID-19 studies use thawed, frozen cells, and dying cells do not survive freeze–thawing; (2) investigation of whether

circulating mononuclear cells are dying is lacking in published studies; and (3) few researchers have looked for monocyte infection because monocytes do not express ACE2. A few previous studies have shown increased IL-1 cytokines in the plasma of patients with COVID-19, in vitro SARS-CoV-2 entry in myeloid cells or NLRP3 inflammasome caspase-1 activation in blood cells of patients with COVID-19<sup>9,10,21,38</sup>. However, no previous study showed that SARS-CoV-2 infection of monocytes is antibody mediated, identified the monocyte receptor, showed that viral replication does not produce infectious virions, identified monocyte infection as the cause of inflammasome activation or showed evidence of pyroptosis. However, two previous studies suggested that monocyte-derived macrophages can be abortively infected<sup>38</sup>. In contrast to our findings, monocyte-derived macrophages weakly express ACE2 and their infection may be partly mediated by ACE2, as in vitro infection in the absence of anti-spike is blocked by anti-ACE2<sup>38</sup>.

FcγR-mediated uptake of antibody-coated virus into monocytes is a double-edged sword. Pyroptosis, which occurs rapidly, probably aborts viral infection before infectious virions are fully assembled. Monocyte/macrophage infection is a dead end for the virus—it removes virions from the extracellular milieu, blocks them from producing infectious progeny and prevents them from disseminating. Pyroptosis in infected monocytes/macrophages also sounds a potent immune alarm to recruit and activate innate and adaptive immune cells to infection sites to mobilize immune defence. By contrast, the inflammatory mediators released from pyroptotic monocytes and macrophages can cause a cytokine storm. It may not be a coincidence that clinical deterioration coincides temporally with the detection of SARS-CoV-2 antibody responses<sup>8,29,39</sup>. In fact, some recent studies suggest that higher antibody titres correlate with disease severity<sup>29,39</sup>.

Pyroptotic myeloid cells are probably a major cause of the serious inflammatory sequelae that lead to acute lung injury, multiorgan damage, vascular leak and respiratory distress in patients with severe disease. In particular, patients with severe COVID-19 had increased plasma biomarkers of pyroptosis compared with patients with mild or moderate COVID-19. However, neither antibody titres nor the proportion of infected ASC-speck-positive monocytes at presentation correlated with severe disease, perhaps because of the small number of samples. Larger cohorts are needed to better assess the relative importance of monocyte/macrophage pyroptosis in severe COVID-19 pathogenesis. The large numbers of infected monocytes and macrophages, the fact that a quarter of lung macrophages have activated inflammasomes, and that myeloid cells are the major source of IL-1 and other inflammatory cytokines make it probable that monocyte/macrophage infection and inflammasome activation are important in severe COVID-19 pathogenesis. Although neutrophils could potentially be infected, infection of freshly isolated COVID-19 neutrophils or in vitro-infected HD neutrophils was not detected. Thus, neutrophil infection is probably not a major contributor to pathogenesis, although neutrophil activation of GSDMD-dependent NETosis (a cell death process involving neutrophil extracellular traps (NETs)) or other features of neutrophil activation may well be important drivers. It will be worthwhile to study other infected cells as potential sources of inflammation, and to understand what aspects of monocyte/macrophage activation enhance infection.

Four times as many lung-resident macrophages had activated inflammasomes as were infected. Further studies are needed to identify what stimulates inflammation in uninfected macrophages, but alarmins released by lung tissue damage are probably culprits. Although inflammasome activation was detected in almost every infected monocyte and macrophage, it was not detected in lung epithelial cells. Why lung epithelial cells resist inflammasome activation will require further study. It is worth examining whether infection might activate inflammasome-independent pyroptosis by other gasdermins in non-myeloid cells in the lungs. NLRP3 and AIM2 inflammasomes that recognize cell membrane damage and cytosolic DNA, respectively, formed in SARS-CoV-2-infected monocytes. Further work is needed to understand how SARS-CoV-2 activates these

inflammasomes, whether activation is restricted to virulent coronaviruses, and whether other inflammasomes are activated, such as NLRP1 and NLRP6, which sense dsRNA<sup>40,41</sup>.

In this study, blocking antibodies against two FcγRs, CD16 and CD64, inhibited monocyte infection. CD64 is expressed on all monocytes, including the dominant classical subtype that is not infected, whereas CD16 is more selectively expressed, and all the infected patient monocytes are CD16 positive. This means that CD16 is probably the major Fc receptor that mediates viral entry into monocytes. Blocking infection by anti-CD64 antibodies may be indirect, as CD64 and CD16 use the same signalling adaptors and associate on the cell surface.

At diagnosis, plasma biomarkers of pyroptosis, including IL-1RA, IL-18, LDH and GSDMD, were increased in patients who developed severe disease—suggesting that they might help to predict prognosis—and who would benefit from immune-modulating therapy. Repurposing FDA-approved drugs that inhibit inflammatory cytokines or GSDMD is worth assessing but, so far, controlled clinical trials evaluating inhibiting inflammatory cytokines (anti-IL-1β (canakinumab), anti-IL-1RA (anakinra), anti-IL-6 and anti-IL-6R) have shown at best weak protection, which may be due to suboptimal timing or because any cytokine is only one of many inflammatory mediators. Two FDA-approved inhibitors of GSDMD, disulfiram (antabuse)<sup>42</sup> and dimethyl fumarate (tecfidera)<sup>43</sup> are currently being evaluated in clinical studies (NCT04485130, NCT04594343 and NCT04381936). In mouse models of sepsis, which has overlapping features with severe COVID-19 disease, these drugs strongly improved survival and reduced plasma IL-6 and TNF.

Our findings, which implicate opsonizing antibodies in monocyte infection and inflammasome activation, suggest that antibodies may contribute to deleterious immune reactions associated with severe disease<sup>44</sup>. FcγR-mediated monocyte infection is an example of antibody-mediated enhancement of infection. Nonetheless, overwhelming evidence shows that vaccine-generated neutralizing antibodies prevent infection and improve the clinical outcome of breakthrough infections, suggesting that anti-spike antibodies are highly beneficial. Plasma from vaccinated individuals did not promote monocyte infection, indicating that antibody-mediated enhancement is not a concern with respect to vaccination. However, therapeutically administered anti-spike neutralizing monoclonal antibodies only improve the clinical outcome if given early, before hospitalization<sup>45,46</sup>, and antibody-containing convalescent sera have not shown clinical benefit<sup>47</sup>. Thus, it is worth considering whether some antibodies might have both protective and deleterious effects<sup>48</sup>. Antibodies are clearly beneficial for blocking infection of ACE2-expressing lung and airway epithelia, in which the virus completes replication to produce infectious progeny. However, antibody properties that affect Fc-receptor-mediated cellular uptake, phagocytosis, cytotoxicity and complement activation can affect disease pathogenesis<sup>28</sup>.

Early development of afucosylated anti-spike antibodies promotes alveolar macrophage inflammation and is associated with COVID-19 severity<sup>33–35</sup>. Afucosylated antibodies are increased during acute infection with enveloped viruses like SARS-CoV-2 but are not abundant after COVID-19 vaccination<sup>49</sup> or other types of antigen exposure<sup>34</sup>. IgG isolated from patients with COVID-19 with a higher proportion of afucosylated antibodies significantly, but weakly, increased in vitro monocyte infection but IgG from patients with fewer afucosylated antibodies did not. The increased pathogenicity of afucosylated antibodies could be secondary to antibody-mediated infection and downstream inflammasome activation in monocytes and macrophages. However, our findings about afucosylation are preliminary and more work is needed to make this association. Characterizing how antibody features, such as afucosylation, sialylation and choice of constant region, alter protective versus deleterious functions of anti-spike antibodies will be important not only for understanding SARS-CoV-2 pathogenesis, but also for choosing the best preparations of convalescent patient plasma and monoclonal antibodies for therapy and/or prevention of severe disease.



## Online content

Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41586-022-04702-4>.

- Hu, B., Guo, H., Zhou, P. & Shi, Z. L. Characteristics of SARS-CoV-2 and COVID-19. *Nat. Rev. Microbiol.* **19**, 141–154 (2021).
- Del Valle, D. M. et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. *Nat. Med.* **26**, 1636–1643 (2020).
- Liu, X., Xia, S., Zhang, Z., Wu, H. & Lieberman, J. Channelling inflammation: gasdermins in physiology and disease. *Nat. Rev. Drug Discov.* **20**, 384–405 (2021).
- Akbar, A. N. & Gilroy, D. W. Aging immunity may exacerbate COVID-19. *Science* **369**, 256–257 (2020).
- Dinarello, C. A. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. *Blood* **117**, 3720–3732 (2011).
- Wu, C. et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. *JAMA Intern. Med.* **180**, 934–943 (2020).
- Vora, S. M., Lieberman, J. & Wu, H. Inflammasome activation at the crux of severe COVID-19. *Nat. Rev. Immunol.* **21**, 694–703 (2021).
- Long, Q. X. et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nat. Med.* **26**, 845–848 (2020).
- Hadjadj, J. et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. *Science* **369**, 718–724 (2020).
- Rodrigues, T. S. et al. Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. *J. Exp. Med.* **218**, e20201707 (2021).
- Chan, A. H. & Schroder, K. Inflammasome signaling and regulation of interleukin-1 family cytokines. *J. Exp. Med.* **217**, e20190314 (2020).
- Filbin, M. R. et al. Longitudinal proteomic analysis of severe COVID-19 reveals survival-associated signatures, tissue-specific cell death, and cell-cell interactions. *Cell Rep. Med.* **2**, 100287 (2021).
- Pan, P. et al. SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to induce hyperinflammation. *Nat. Commun.* **12**, 4664 (2021).
- Sharma, D. & Kanneganti, T. D. The cell biology of inflammasomes: mechanisms of inflammasome activation and regulation. *J. Cell Biol.* **213**, 617–629 (2016).
- Fung, S.-Y., Yuen, K.-S., Ye, Z.-W., Chan, C.-P. & Jin, D.-Y. A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses. *Emerg. Microbes Infect.* **9**, 558–570 (2020).
- Irving, A. T., Ahn, M., Goh, G., Anderson, D. E. & Wang, L. F. Lessons from the host defences of bats, a unique viral reservoir. *Nature* **589**, 363–370 (2021).
- Davis, M. A. et al. Calpain drives pyroptotic vimentin cleavage, intermediate filament loss, and cell rupture that mediates immunostimulation. *Proc. Natl Acad. Sci. USA* **116**, 5061–5070 (2019).
- Spel, L. & Martinon, F. Detection of viruses by inflammasomes. *Curr. Opin. Virol.* **46**, 59–64 (2021).
- Rogers, C. et al. Gasdermin pores permeabilize mitochondria to augment caspase-3 activation during apoptosis and inflammasome activation. *Nat. Commun.* **10**, 1689 (2019).
- Swanson, K. V. et al. A noncanonical function of cGAMP in inflammasome priming and activation. *J. Exp. Med.* **214**, 3611–3626 (2017).
- Zheng, J. et al. Severe acute respiratory syndrome coronavirus 2-induced immune activation and death of monocyte-derived human macrophages and dendritic cells. *J. Infect. Dis.* **223**, 785–795 (2021).
- Song, X. et al. Little to no expression of angiotensin-converting enzyme-2 on most human peripheral blood immune cells but highly expressed on tissue macrophages. *Cytometry A*, <https://doi.org/10.1002/cyto.a.24285> (2020).
- Ragotte, R. J. et al. Human basigin (CD147) does not directly interact with SARS-CoV-2 spike glycoprotein. *mSphere* **6**, e0064721 (2021).
- Shilts, J., Crozier, T. W. M., Greenwood, E. J. D., Lehner, P. J. & Wright, G. J. No evidence for basigin/CD147 as a direct SARS-CoV-2 spike binding receptor. *Sci. Rep.* **11**, 413 (2021).
- Wang, K. et al. CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. *Signal Transduct. Target. Ther.* **5**, 283 (2020).
- Bruhns, P. & Jonsson, F. Mouse and human FcR effector functions. *Immunol. Rev.* **268**, 25–51 (2015).
- Ong, S.-M. et al. A novel, five-marker alternative to CD16–CD14 gating to identify the three human monocyte subsets. *Front. Immunol.* **10**, 1761 (2019).
- Bournazos, S., Gupta, A. & Ravetch, J. V. The role of IgG Fc receptors in antibody-dependent enhancement. *Nat. Rev. Immunol.* **20**, 633–643 (2020).
- Li, K. et al. Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19. *Nat. Commun.* **11**, 6044 (2020).
- Weber, F., Wagner, V., Rasmussen, S. B., Hartmann, R. & Paludan, S. R. Double-stranded RNA is produced by positive-strand RNA viruses and DNA viruses but not in detectable amounts by negative-strand RNA viruses. *J. Virol.* **80**, 5059–5064 (2006).
- Xie, X. et al. An infectious cDNA clone of SARS-CoV-2. *Cell Host Microbe* **27**, 841–848 (2020).
- Clark, S. A. et al. Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2. Preprint at [bioRxiv](https://doi.org/10.1101/2020.11.13.381533) <https://doi.org/10.1101/2020.11.13.381533> (2020).
- Chakraborty, S. et al. Proinflammatory IgG Fc structures in patients with severe COVID-19. *Nat. Immunol.* **22**, 67–73 (2021).
- Larsen, M. D. et al. Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity. *Science* **371**, eabc8378 (2021).
- Hoepel, W. et al. High titers and low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation by alveolar macrophages. *Sci. Transl. Med.* **13**, eabf8654 (2021).
- Ackermann, M. et al. Patients with COVID-19: in the dark-NETs of neutrophils. *Cell Death Differ.* **28**, 3125–3139 (2021).
- Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell* **181**, 271–280 (2020).
- Hui, K. P. Y. et al. Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures. *Lancet Respir. Med.* **8**, 687–695 (2020).
- Garcia-Beltran, W. F. et al. COVID-19-neutralizing antibodies predict disease severity and survival. *Cell* **184**, 476–488 (2021).
- Shen, C. et al. Phase separation drives RNA virus-induced activation of the NLRP6 inflammasome. *Cell* **184**, 5759–5774 (2021).
- Bauernfried, S., Scherr, M. J., Pichlmair, A., Duderstadt, K. E. & Hornung, V. Human NLRP1 is a sensor for double-stranded RNA. *Science* **371**, eabd0811 (2021).
- Hu, J. J. et al. FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation. *Nat. Immunol.* **21**, 736–745 (2020).
- Humphries, F. et al. Succination inactivates gasdermin D and blocks pyroptosis. *Science* **369**, 1633–1637 (2020).
- Iwasaki, A. & Yang, Y. The potential danger of suboptimal antibody responses in COVID-19. *Nat. Rev. Immunol.* **20**, 339–341 (2020).
- Weinreich, D. M. et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. *N. Engl. J. Med.* **384**, 238–251 (2021).
- Gupta, A. et al. Early treatment for COVID-19 with SARS-CoV-2 neutralizing antibody sotrovimab. *N. Engl. J. Med.* **385**, 1941–1950 (2021).
- Korley, F. K. et al. Early convalescent plasma for high-risk outpatients with COVID-19. *N. Engl. J. Med.* **385**, 1951–1960 (2021).
- Zhou, Y. et al. Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD. *Cell Rep.* **34**, 108699 (2021).
- Chakraborty, S. et al. Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity. *Sci. Transl. Med.* **14**, eabm7853 (2022).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s), under exclusive licence to Springer Nature Limited 2022

## Methods

### Human participants

**Fresh PBMCs and plasma cohort.** The study was approved by the Investigation Review Boards of Boston Children's Hospital and Massachusetts General Hospital (MGH), and all of the enrolled patients signed an informed consent. A total of 73 patients aged 18 years or older with clinical symptoms suggestive of COVID-19 infection were enrolled at the time of presentation to the MGH emergency department (ED) from 9 July 2020 to 15 October 2021. A 10-ml EDTA blood sample was transported to Boston Children's Hospital and processed within 2 h of collection. Samples from patients with COVID-19 were all RT-qPCR verified for SARS-CoV-2 infection on the day on which blood was drawn. Patients who presented to the ED with COVID-19-like symptoms, but were PCR negative, were used as non-COVID-19 samples. Patients who had received SARS-CoV-2 vaccination before presentation were excluded from the study. A summary of demographic and clinical data is provided in Supplementary Table 1. HD samples were processed and analysed in parallel with the patient samples. The participants were enrolled from 9 July 2020 to 10 January 2021 at Boston Children's Hospital (BCH) with IRB-approved waiver of informed consent. Vaccinated HDs ( $n = 6$ ), who received two doses of the Pfizer-BioNTech mRNA vaccine, were enrolled 3 weeks after the second dose and their plasma was pooled to evaluate whether it promoted monocyte infection.

**Frozen plasma cohort.** A total of 60 patients aged 18 years or older with clinical symptoms suggestive of COVID-19 infection were enrolled in the MGH ED from 15 March 2020 to 15 April 2020 with an IRB-approved waiver of informed consent. The enrolled patients had at least one of the following: (1) tachypnea,  $\geq 22$  breaths per minute; (2) oxygen saturation,  $\leq 92\%$  on room air; (3) requirement for supplemental oxygen; and (4) positive-pressure ventilation. A 10-ml EDTA tube was obtained with the initial clinical blood draw in the ED ( $n = 60$ ). Blood was also obtained on days 3 ( $n = 42$ ) and 7 ( $n = 35$ ) if the patient was hospitalized on those dates. Clinical course was followed for 28 days after enrolment or until hospital discharge if after 28 days. SARS-CoV-2-confirmed patients (by RT-qPCR) were assigned a maximum acuity score (A1–A5) (A1, died; A2, required mechanical ventilation; A3, hospitalized requiring supplemental oxygen; A4, hospitalized but not requiring supplemental oxygen; and A5, discharged and not requiring hospitalization)<sup>12</sup>. Patients were grouped on the basis of their worst acuity score over 28 days and divided into three groups for comparison (A1 and A2, severe disease; A3, moderate disease; and A4 and A5, mild disease). Only 1 patient was in A4; most of the mild patients therefore represent those who were discharged immediately from the ED and therefore have only a day-0 sample. A summary of the demographic and clinical data for each outcome group is provided in Supplementary Table 2.

**Lung tissue samples.** Lung samples from five individuals who died from COVID-19 (Supplementary Table 3) and three individuals who died from trauma and without lung disease were obtained from MGH. The study was approved by the institutional review board of MGH IRB 2020P001147. Informed consent was obtained from the relatives of study participants. Lung tissue specimens were obtained within 24 h of autopsy and immediately formalin-fixed and embedded in paraffin.

### Reagents and antibodies

A list of reagents and antibodies and their sources is provided in Supplementary Table 4.

### Plasma, PBMC, neutrophil and monocyte isolation

Samples were processed using the recommended safety precautions in a BSL-2+ facility. Blood tubes were centrifuged at 2,000 rpm for 10 min to separate the plasma from blood cells. The plasma was collected in a new tube and incubated or not with 1% Triton X-100 for 1 h on ice before

aliquoting and freezing at  $-80^{\circ}\text{C}$ . Blood cells were resuspended in PBS and layered over Ficoll for density centrifugation. PBMCs were collected from the interface and subjected to red blood cell lysis (if necessary) with Red Blood Cell Lysing Buffer Hybri-Max for 5 min on ice, followed by quenching with RPMI medium supplemented with 10% FBS and 1% penicillin-streptomycin. PBMCs were washed once more with RPMI and one fraction was stained for flow cytometry, while the remaining cells were used for monocyte purification by negative selection using the RosetteSep Human Monocyte Enrichment Cocktail. Neutrophils of patients with COVID-19 were isolated from the whole blood by immunomagnetic negative selection using the EasySep Direct Human Neutrophil Isolation Cocktail, according to the manufacturer's instructions. HD monocytes for *in vitro* infection were purified from PBMCs by positive selection with CD14<sup>+</sup> magnetic beads. The red blood cell pellet from the Ficoll density centrifugation was used to isolate neutrophils from the same HD samples. Neutrophils were separated from the RBC pellet by hypotonic lysis.

### Cell lines

The THP-1 monocytic cell line and Vero E6 cells were obtained from ATCC. A549 cells and HEK293T cells overexpressing *ACE2* were obtained from the MassCPR variants repository at Ragon Institute. *ACE2* expression was validated by RT-qPCR and anti-*ACE2* flow cytometry. All cells were tested for mycoplasma contamination.

### Multiplex luminex, immunoassay and LDH activity assay

IL-1RA, IL-2, IL-4, IL-5, IL-6, IL-7, IL-10, IL-12, IL-13, IL-17, IL-18, IL-21, IL-23, CCL3, CCL7, CCL9, CXCL10, G-CSF, TNF, IFN $\beta$  and IFN $\gamma$  were measured in plasma samples using a custom Luminex assay (R&D Systems) according to the manufacturer's instructions. Sample data were acquired using the Luminex xPONENT 4.2 for MAGPIX Analyzer at the Analytical Instrumentation Core Lab of Boston University and analysed with Milliplex Analyst v5. The plasma levels of IL-1 $\beta$  were measured using the Simple Plex cartridge Ella (ProteinSimple) according to the manufacturer's instructions at the BCH. All of the samples were diluted 1:3 with the dilution buffer and the analytical performance was conducted on the ProteinSimple Ella automated immunoassay platform (Bio-Techne). The samples were acquired using the Simple Plex Runner v.3.7.2.0 software and analysed using Simple Plex Explorer 3.7.2.0. GSDMD was measured in the same samples using the Human GSDMD ELISA kit (MyBiosource) according to the manufacturer's instructions and LDH activity was measured using the CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega). Results from the latter assays were analysed using the Biotek Synergy 2 analyzer; GSDMD absorbance was measured at 450 nm and LDH absorbance was measured at 490 nm. Absorbance levels were quantified by linear regression based on the standard curve.

### Anti-spike RBD ELISA

The enzyme-linked immunosorbent assay (ELISA) anti-spike RBD kit (BioLegend) was used to quantify antigen-specific IgG in the plasma from HDs, non-COVID-19 patients and patients with COVID-19. ELISA was performed according to the manufacturer's instructions. Anti-spike RBD absorbance was measured at 450 nm and 570 nm and quantified by linear regression based on the standard curve.

### Intracellular staining for imaging flow cytometry and confocal microscopy

Fixed monocytes were permeabilized with 0.1% Triton X-100 for 10 min and washed twice with PBS + 3% FBS. Monocytes were then blocked for 30 min with PBS + 5% FBS, washed twice and then stained with unconjugated primary antibodies against ASC (1:200, mouse or rabbit), NLRP3 (1:200, goat), AIM2 (1:200, mouse), GSDMD (1:200, mouse), pyrin (1:200, rabbit), dsRNA (J2, mouse) (1:500) or SARS-CoV-2 nucleocapsid protein (1:500, rabbit) for 2 h, followed by three washes with PBS + 3% FBS. The cells were then stained with secondary antibodies (donkey

# Article

anti-mouse, rabbit or goat conjugated with Alexa Fluor 488, 546 or 647, at 1:1,000) for 1 h in PBS + 3% FBS, followed by three washes. Untreated THP-1 cells, THP-1 cells treated with LPS + nigericin or transfected with Poly(dA:dT) using Lipofectamine 2000, and HEK293T cells (negative control) were stained with anti-NLRP3 and anti-AIM2 antibodies for antibody validation.

For microscopy analysis, cells were fixed and then stained with DAPI (1:1,000) for 10 min, washed three times and cytospun onto glass slides (VWR), and sealed using polyvinyl alcohol and 1.5 mm coverslips (VWR). Confocal images were acquired using the Zeiss LSM 800 system with 405-nm, 488-nm, 561-nm and 633-nm lasers (emission filters, 465 nm, 509 nm, 561 nm and 668 nm, respectively) and a  $\times 40$  or  $\times 63$  1.4 NA oil-immersion objective. Images were acquired using Zen Black 2.0 and processed using Zen Blue 3.2.

For imaging flow cytometry, cells were resuspended in PBS + 3% FBS for analysis. Data were acquired using the ImageStream X MKII system with  $\times 60$  magnification (Amnis), the INSPIRE v.2 acquisition software and were analysed using IDEAS v.6.2 (Amnis). Monocytes were gated based on area/aspect ratio. ASC, NLRP3, AIM2 and pyrin specks were gated and quantified on the basis of fluorophore intensity/maximum pixels.

## Flow cytometry

PBMCs were washed and stained for viability with Zombie Yellow in PBS (1:200) for 15 min on ice. Cells were washed with PBS, centrifuged and then stained with anti-annexin V PE (1:200) antibodies in  $1\times$  annexin buffer for 15 min on ice. After washing with  $1\times$  annexin V buffer, cells were blocked for 10 min with anti-CD32 (1:100) in PBS + 3% FBS, and then stained for 15 min on ice with a cocktail of antibodies to identify lymphocyte and myeloid cell subsets (all 1:200 except CD19 BV650, CD123 PerCP-Cy5.5 and CD56 APC-Cy7, 1:100). Purified monocytes and an A549 cell line overexpressing ACE2 were blocked with anti-CD32, then stained with primary antibodies for ACE2 (1:100) for 15 min on ice. The secondary anti-goat AF488 antibody was co-incubated with anti-CD14 PE-Cy7 (1:200) and anti-CD147 APC (1:100) antibodies. After the last wash, cells were resuspended in 2% PFA and kept at 4 °C until flow cytometry analysis. In vitro-infected monocytes were fixed and permeabilized with 0.1% Triton X-100, then blocked with PBS + 5% FBS. Cells were stained with primary antibodies for dsRNA (J2, mouse) (1:500), then stained with secondary antibodies (donkey anti-mouse conjugated with Alexa Fluor 647, at 1:500) and anti-CD14 PE-Cy7 antibodies. Cells were acquired using the FACS Canto II or LSR II using the FACSDiva v7 acquisition software, and data were analysed using FlowJo v.10.7.1.

## FLICA assay

Freshly isolated monocytes were washed and resuspended in RPMI 10% FBS with FLICA substrate (BioRad FAM-FLICA Caspase-1 kit) and cultured for 1 h at 37 °C. Cells were then washed twice with  $1\times$  apoptosis buffer (from the kit) and fixed with  $1\times$  fixative (from the kit). Cells were kept at 4 °C until further staining and analysis.

## Immunoblot analysis

Lysates of enriched monocytes from HDs and patients with COVID-19, the former treated or not for 16 h at 37 °C with 100 ng ml<sup>-1</sup> LPS and 20  $\mu$ M nigericin, were resolved on 12% SDS-PAGE gels, transferred to nitrocellulose membranes and blotted to detect GSDMD using (Abcam ab210070) primary rabbit monoclonal antibodies and secondary anti-rabbit IgG. The membranes were also blotted for  $\beta$ -actin and COX-IV.

## Immunofluorescence analysis of lung samples

Formalin-fixed and paraffin-embedded lung parenchymal samples were stained for SARS-CoV-2 N, ASC and CD14, and immunofluorescence was analysed on the Leica Bond RX automated staining platform using the Leica Biosystems Refine Detection Kit (Leica). The antibody for

SARS nucleocapsid (Novus) was run with citrate antigen retrieval and tagged with Alexa Fluor 488 Tyramide (Life). After citrate stripping, the antibody for CD14 (Cell Signaling) was incubated and tagged with Alexa Fluor 594 Tyramide (Life). After EDTA stripping, staining for ASC (Santa Cruz) was analysed using antibodies tagged with Alexa Fluor 647 Tyramide (Life). EDTA stripping was performed before anti-CD31 or anti-E-cadherin staining tagged to Alexa Fluor 555 Tyramide (Life). The samples were counterstained with DAPI. The slides were scanned using the Aperio Versa Digital Pathology Scanner (Leica) and analysed using Aperio ImageScope v.12.4.3 (Leica). The slides were also analysed by confocal microscopy as described above.

## In vitro SARS-CoV-2 infection

icSARS-CoV-2-mNG (a molecular clone of SARS-CoV-2 expressing Neon Green (NG) fluorescent protein) was a gift to A.E.G. from S. P. Yong and the World Reference Center for Emerging Viruses and Arboviruses<sup>31</sup>. The NG fusion protein is expressed only during viral replication. The SARS-CoV-2 US-WA1/2020 ancestral (WA) variant was obtained from BEI Resources. The B.1.617.1/Delta variant isolate was obtained from the MassCPR variant repository. In brief, the variant was isolated at the Ragon BSL3 by rescue on Vero-E6 cells from primary clinical specimens. The whole genome of subsequent viral stocks was sequenced to confirm that no additional mutation arose during virus expansion. HD monocytes/neutrophils were purified from apheresis leukoreduction collars collected at Brigham and Women's Hospital. Monocytes were incubated overnight with medium or 100 ng ml<sup>-1</sup> LPS, and then infected with icSARS-CoV-2-mNG, SARS-CoV-2 (WA) and SARS-CoV-2 B.1.617.1/Delta (multiplicity of infection (MOI) = 1) in a BSL-3 facility. Infection of A549-ACE2 cells at an MOI of 0.01 was used as a control. The viral inoculum was treated with 10  $\mu$ g ml<sup>-1</sup> of antibody (isotype control mAb114, anti-spike C1A-H12, or anti-spike C1A-B12), or 5% pooled plasma (heat-inactivated or not; Ig-depleted or not, as indicated) from HDs ( $n = 3$ ), patients with COVID-19 of mixed disease severity ( $n = 12$  (total),  $n = 4$  (mild),  $n = 4$  (moderate),  $n = 4$  (severe)) or vaccinated HDs ( $n = 6$ ) before infection with SARS-CoV-2 for 30 min at room temperature. Treated virus (100  $\mu$ l) was added to monocytes ( $2 \times 10^6$  cells per well) in 48-well plates. Infected cells were incubated at 37 °C under 5% CO<sub>2</sub> with gentle shaking every 10 min for 1 h, after which the culture volume was increased to 500  $\mu$ l with RPMI supplemented with 5% heat-inactivated normal AB human serum and 10  $\mu$ g ml<sup>-1</sup> of the aforementioned antibodies, or 5% pooled plasma from HDs or patients with COVID-19. Cultures were then incubated at 37 °C under 5% CO<sub>2</sub> for 48 h, at which time the cells were collected and fixed for 20 min with 4% PFA and then stained.

IgG from the pooled plasma of patients with COVID-19 was depleted by protein A/G agarose resin and IgA depleted by peptide M agarose. Control samples were incubated with agarose resin without coupled protein. C1A-B12 and C1A-H12, two SARS-CoV-2 spike-targeting human monoclonal antibodies, were produced as previously described<sup>32</sup>. For blocking experiments, cells were incubated with 10  $\mu$ g ml<sup>-1</sup> monoclonal antibodies, anti-CD16, anti-CD32 (clone IV.3 (Fig. 4j and Extended Data Fig. 5a), clone 6C4 (Fig. 4k and Extended Data Fig. 5b, c)), anti-CD64, anti-ACE2 and anti-CD147 for 30 min, before virus infection. For antiviral drug treatment, monocytes were incubated at 37 °C under 5% CO<sub>2</sub> for 1 h with 10  $\mu$ M remdesivir (GS-5734) or camostat mesylate before infection. To find an appropriate remdesivir concentration, serial dilutions between 10 and 80  $\mu$ M were analysed. To compare plasma obtained from patients with different disease severity, plasma was pooled on the basis of the MGH acuity score (A1–A5), as described above.

To test the role of IgG afucosylation, IgG purified from serum samples of patients with COVID-19 was analysed by mass spectrometry to define the percentage of afucosylation as described previously<sup>33</sup>. Low afucosylated samples, provided by T. Wang, contained  $8.4 \pm 0.7\%$  afucosylated IgG and high afucosylated samples,  $30.1 \pm 1.5\%$  afucosylated IgG. IgG was also purified from pooled plasma from HDs and patients with COVID-19 using the Melon gel IgG Spin Purification Kit (Thermo

Fisher Scientific) according to the manufacturer's instructions. Virus was preincubated with 10  $\mu\text{g ml}^{-1}$  of purified IgG and the infection was performed as described above.

### RT-qPCR

RNA was extracted using Trizol reagent (Invitrogen) from monocytes of patients with COVID-19 or from uninfected or infected HD monocytes (stimulated or not with LPS (100  $\text{ng ml}^{-1}$  for 16 h)), then reverse-transcribed using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Random primers were used to generate cDNA for detection of cellular RNAs (*ACE2*, *BSG* and *ACTB*) and SARS-CoV-2-specific primers were used to generate cDNA to detect viral genomic RNAs (N1 region of *N* gene)<sup>50</sup>. cDNA was analysed by RT-qPCR using the SsoFast EvaGreen Supermix (BioRad) (30 s at 95 °C; then 40 cycles of 3 s at 95 °C and 3 s at 54 °C) in the CFX96 Touch Real-Time PCR Detection System (BioRad) using the CFX Manager v.1.6 acquisition/analysis software. To detect SARS-CoV-2 sgRNA, RT-qPCR was performed using a primer pair with the forward primer annealing to the 5' leader region of the viral genome and the reverse primer annealing to the 3' UTR. With the cycling conditions used (30 s at 95 °C; then 40 cycles of 30 s at 95 °C, 30 s at 60 °C and 90 s at 72 °C), full-length gRNA was not amplified, but small sgRNA segments (<3 kb) could be amplified<sup>16,51,52</sup>. For each sample,  $C_t$  values were normalized to the *ACTB*  $C_t$  value. Primer sequences are provided in Supplementary Table 4. sgRNA qPCR products were also analysed by electrophoresis on 1% agarose gels stained with ethidium bromide and visualized on the Chemidoc imager (BioRad). The approximately 1,600 nucleotide band was excised and sequenced to confirm its origin as the SARS-CoV-2 sgRNA encoding *N*.

### Plaque assays

Vero E6 cells were seeded as monolayers in 24-well plates 1 day before infection. Virus-infected sample culture supernatants were serially diluted in DMEM. The plates were washed once with DPBS and then infected with 100  $\mu\text{l}$  of diluted sample and incubated at 37 °C under 5%  $\text{CO}_2$  for 1 h with rocking every 15 min. After 1 h, the inoculum was removed and an overlay of 1% methylcellulose (Sigma-Aldrich) in complete MEM (Gibco) was applied to each well. The plates were incubated at 37 °C until plaques were observable in positive control wells. To visualize plaques, the overlay was removed, and the cell monolayer was fixed with 4% PFA and stained with crystal violet. Plaques were then counted to quantify the virus titre in PFU per ml.

### Statistical analysis

Statistical analysis was performed using GraphPad Prism v.9.0. Normal distribution of the data was evaluated using the D'Agostino and Pearson normality test before applying statistical methods. Distributions were considered to be normal if  $P \leq 0.05$ . Parametric or nonparametric (Mann-Whitney *U*-test) two-tailed unpaired *t*-tests were used to compare two unpaired groups. Multiple-group comparisons were analysed using one-way ANOVA with Sidak or Tukey multiple-comparisons tests, or nonparametric Kruskal-Wallis with Dunn post-test. Multiple groups

were compared using two-way ANOVA with additional Sidak or Tukey multiple-comparisons test. Mean plasma values from hospitalized patients with COVID-19 on each day were compared between severity groups by multiple unpaired *t*-tests. Correlations of plasma levels were determined by simple linear regression and Pearson correlation coefficient.

### Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this paper.

### Data availability

The data and materials supporting the findings of this study are available from the corresponding authors on request.

50. Division of Viral Diseases, NCIRD. 2019-Novel Coronavirus (2019-nCoV) Real-Time rRT-PCR Panel Primer and Probes, <https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html> (CDC, 2020).
51. Kim, D. et al. The architecture of SARS-CoV-2 transcriptome. *Cell* **181**, 914–921 (2020).
52. Perera, R. et al. SARS-CoV-2 virus culture and subgenomic RNA for respiratory specimens from patients with mild coronavirus disease. *Emerg. Infect. Dis.* **26**, 2701–2704 (2020).

**Acknowledgements** We thank members of the MGH COVID-19 collection and the processing team (K. Lavin-Parsons, B. Lilley, C. Lodenstein, B. McKaig, N. Charland, H. Khanna, A. Gonye, I. Gushterova, T. Lasalle, N. Sharma, B. C. Russo, M. Rojas-Lopez, M. Sade-Feldman, K. Manakongtreecheep, J. Tantivit and M. Fisher Thomas) for plasma samples; T. Wang for providing the high and low afucosylated IgGs from donors with COVID-19; the members of the Analytical Instrumentation Core Lab of Boston University for running and analysing the Luminex Multiplex assay; D. Briscoe and L. Sheward for analysing IL-1 $\beta$ ; the staff at the Specialized Histopathology Core of the Dana-Farber/Harvard Cancer Center (supported in part by an NIH P30CA06516) for histology and immunohistochemistry; the staff at the MassCPR variants repository (funded by the Massachusetts Consortium on Pathogen Readiness) for providing viral strains and ACE2-overexpressing cell lines; and the staff at the Ragon Institute BSL3 laboratory (funded by the Harvard Center for AIDS Research (NIH P30AI060354)) and the Massachusetts Consortium on Pathogen Readiness. This research was supported by the Lemann Brazil Research Fund (to J.L. and C.J.); the National Institutes of Health grant R01AI124491 (to H.W.); the National Institutes of Health grant U19AI131135 (to L.G.); the Annenberg Foundation and FAST grants and a gift from J. Sullivan (to A.E.G.); the American Lung Association (to M.B.G. and M.R.F.); the British Heart Foundation Programme grant RG/16/4/32218 (to S.B.); a Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) fellowship (to C.J.); a Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) fellowship (to L.B.d.L.); and the National Institutes of Health training grant T32AI007245-31A1 (to M.L.).

**Author contributions** All of the authors contributed to preparing the manuscript. Conceptualization: J.L., C.J., A.C. and H.W. Experimentation: C.J., A.C., S. Ranjbar, L.B.d.L., M.L., J.I., S. Ravid, F.H., M.R.S., J.B., S.H., S.M.V., L.A.H., E.J., V.L., B.P., G.M. and S.B. Patient recruitment: C.B., J.M., N.R., U.D.A., D.K., M.R.F., M.B.G. and K.K. Data analysis: C.J., A.C., J.I., S.B. and C.S. Reagents: S.C. and J.A. Supervision: J.L., C.J., A.C., L.G. and A.E.G. Manuscript writing: C.J., A.C., J.I. and J.L.

**Competing interests** The authors declare no competing interests.

### Additional information


**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s41586-022-04702-4>.

**Correspondence and requests for materials** should be addressed to Caroline Junqueira, Michael R. Filbin or Judy Lieberman.

**Peer review information** Nature thanks Stanley Perlman, Gestur Vidarsson and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.


**Reprints and permissions information** is available at <http://www.nature.com/reprints>.






**Extended Data Fig. 1 | Identification of lymphocyte and monocyte subsets in healthy donors and COVID-19 patients.** Flow cytometry gating strategy for identifying lymphocytes and monocytes in Fig. 1a, b (a) and for identifying

monocyte subpopulations in Fig. 1c (b). Monocyte subpopulations: CL - classical CD14<sup>hi</sup>CD16<sup>-</sup>; ITM - intermediate CD14<sup>hi</sup>CD16<sup>+</sup>; NCL - non-classical CD14<sup>lo</sup>CD16<sup>+</sup>.




**Extended Data Fig. 2 | Inflammasome imaging and GSDMD cleavage analysis.** **a**, Gating strategy for imaging flow cytometry analysis of isolated monocytes. **b**, Representative imaging flow cytometry images of GSDMD and ASC staining in COVID-19 patient monocytes that lacked ASC specks. **c**, **d**, Representative imaging flow cytometry images of HEK293T cells (negative control) and THP-1 cells untreated or treated with LPS+nigericin or transfected with poly(dA:dT), then stained with anti-NLRP3 (**c**) and anti-AIM2 (**d**). **e**, Single staining controls for antibody staining. Representative images of monocytes

from COVID-19 patients shown were stained with 1° ASC - 2° AF488; 1° NLRP3 - 2° AF568; 1° GSDMD, Pyrin, AIM2, J2, N - 2° AF647; or FAM FLICA Caspase-1 fluorescence, and Zombie Yellow dye. FLICA<sup>+</sup> and Zombie<sup>+</sup> cells in cells undergoing pyroptosis; GSDMD, Pyrin, AIM2 and NLRP3 in non-pyroptotic cells (diffuse staining); J2<sup>+</sup> and N<sup>+</sup> in infected monocytes. Scale bar, 7  $\mu$ m (**b-e**). **f**, Representative confocal image z-stacks and plane projections of monocytes of HD and COVID-19 patients, stained for the same markers as in Figure 2. Scale bars, 5  $\mu$ m. **g**, Full scan images for blots shown in Fig. 2g.



**Extended Data Fig. 3 | ACE2 and CD147 expression on circulating monocytes.** Purified blood monocytes from HD ( $n = 3$ ), COVID-19 patients ( $n = 4$ ) and A549-ACE2 ( $n = 3$ ) were analysed by flow cytometry (a, c) and RT-qPCR (b, d) for expression of ACE2 (a, b) or CD147 (*BSG*) (c, d). HD monocytes were treated or not with LPS before analysis. A549-ACE2 cells were


used as positive control. Mean  $\pm$  S.E.M. is shown. \* $p < 0.05$ , \*\*\* $p < 0.001$ , \*\*\*\* $p < 0.0001$  relative to isotype (Iso) control antibody-stained, LPS-activated HD monocytes (a, c) by one-way ANOVA with Tukey's multiple comparisons test. Data are representative of 2 independent experiments.



**Extended Data Fig. 4 | Effect of anti-spike monoclonal antibodies or pooled COVID-19 plasma on in vitro infection of healthy donor purified monocytes with icSARS-CoV-2-mNG. a-e**, HD monocytes ( $n = 3$ ) were primed with LPS, infected with icSARS-CoV-2-mNG (MOI, 1), then stained 48 h later for nucleocapsid (N) or dsRNA (J2) and ASC and analysed by imaging flow cytometry. Before infection, virus was preincubated with indicated monoclonal antibodies (IgG1 isotype control mAb114 (Iso)), non-neutralizing anti-spike (C1A-H12 (H12)) or neutralizing anti-RBD (C1A-B12 (B12)) or with pooled HD or COVID-19 patient plasma that had been heat-inactivated (HI) or

not. U, uninfected. Quantification of HD monocyte staining for N (a), J2 (b), NG (c, e) or ASC specks (d). (e) Shows the percentage of N<sup>+</sup> cells that were also NG fluorescent. f, g, A5490-ACE2 ( $n = 3$ ) (f) or LPS-primed HD monocytes ( $n = 3$ ) (g) were infected at the indicated MOI with icSARS-CoV-2-mNG (NG), a molecular clone of the Washington (WA) strain, or with clinical WA and Delta strains. Infection was measured by N staining and flow cytometry. Mean  $\pm$  S.E.M. is shown. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , \*\*\*\* $p < 0.0001$  by one-way ANOVA with Tukey's multiple comparisons test, relative to Iso or as indicated (a-g). Data are representative of 2 independent experiments.





**Extended Data Fig. 5 | In vitro infection of healthy donor monocytes and neutrophils.** **a–c**, LPS-primed HD monocytes ( $n = 3$ ) (**a**, **b**) or purified HD neutrophils ( $n = 3$ ) (**c**) were infected with icSARS-CoV-2-mNG (MOI, 1), then stained 48 h later for nucleocapsid (N) or analysed for NG fluorescence (**c**, right). Before infection, virus was preincubated with COVID-19 plasma, depleted or not of IgG as indicated, and infection was carried out in the presence of indicated blocking or isotype (Iso) control antibodies (**a–c**). The monocyte and neutrophil infections in (**b**) and (**c**) were performed with cells isolated from the same HDs. **d**, Freshly isolated neutrophils, enriched by negative selection, from HD ( $n = 3$ ) and COVID-19 patients of mixed disease severity ( $n = 4$ ) were stained for N and analysed by flow cytometry to assess in vivo infection. **e**, Infection of LPS-primed HD monocytes ( $n = 3$ ) with

icSARS-CoV-2-mNG in the presence of pooled COVID-19 patient plasma, depleted or not of IgG as indicated, and antiviral drugs, Camostat and Remdesivir. **f**, Infection of A549-ACE2 ( $n = 3$ ) with icSARS-CoV-2-mNG to verify the inhibitory activity of 10 μM Remdesivir. Infection was measured by N staining and flow cytometry. **g**, Infection of A549-ACE2 ( $n = 3$ ) and HD monocytes ( $n = 3$ ) with icSARS-CoV-2-mNG in the presence of anti-ACE2 blocking antibody at different concentrations. Infection was measured by NG fluorescence. Mean ± S.E.M. is shown. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , by one-way ANOVA with Tukey's multiple comparisons test (**a–c**, **g**), nonparametric unpaired  $t$ -test (**d**, **f**) and two-tailed nonparametric unpaired multiple  $t$ -test (**e**). Data are representative of 2 replicate experiments.

## Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

### Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

- |     |           |
|-----|-----------|
| n/a | Confirmed |
|-----|-----------|
- The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement
  - A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
  - The statistical test(s) used AND whether they are one- or two-sided  
*Only common tests should be described solely by name; describe more complex techniques in the Methods section.*
  - A description of all covariates tested
  - A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
  - A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
  - For null hypothesis testing, the test statistic (e.g.  $F$ ,  $t$ ,  $r$ ) with confidence intervals, effect sizes, degrees of freedom and  $P$  value noted  
*Give  $P$  values as exact values whenever suitable.*
  - For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
  - For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
  - Estimates of effect sizes (e.g. Cohen's  $d$ , Pearson's  $r$ ), indicating how they were calculated

*Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

### Software and code

Policy information about [availability of computer code](#)

#### Data collection

Flow cytometry data were acquired with FACSDiva v 7.0 (BD)  
Imaging Flow cytometry data were acquired with INSPIRE v 2 (Amnis - Millipore)  
GSDMD ELISA and LDH activity assay data were acquired with Gen5 (BioTek)  
Luminex Multiplex assay data were acquired with Luminex xPONENT 4.2 for MagPix  
Confocal microscopy images were acquired with Zen Black 2.0 (Zeiss)  
Pathology immunofluorescence slides were acquired with Aperio Versa console software v 1.0.4.125.  
qPCR data were acquired with BioRad CFX Manager Software v 1.6  
IL-1b quantification by Ella was acquired with Simple Plex Runner 3.7.2.0

#### Data analysis

Flow cytometry data were analyzed with FlowJo v 10.7.1 (BD)  
Imaging Flow Cytometry data were analyzed with IDEAS v 6.2 (Amnis - Millipore)  
Luminex Multiplex assay data were analyzed with Milliplex Analyst v 5 (VigeneTech)  
Confocal microscopy images were processed with Zen Blue v 3.2 (Zeiss)  
qPCR data were analyzed with BioRad CFX Manager Software v 1.6  
Pathology immunofluorescence slides were analyzed with Aperio ImageScope v 12.4.3  
Graph design and statistical analysis were performed with GraphPad Prism v 9.0.  
IL-1b quantification by Ella was analyzed with Simple Plex Explorer 3.7.2.0

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research [guidelines for submitting code & software](#) for further information.

## Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

SARS-CoV-2 isolated variants are available at MassCPR variant repository.

The minimum dataset necessary to interpret the findings are included in the article. Any further data that support the findings of this study are available from the corresponding authors upon request.

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences       Behavioural & social sciences       Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	<p>Our study enrolled 73 patients presenting at the Massachusetts General Hospital (MGH) emergency department (ED) (Boston, USA) with clinical symptoms suggestive of COVID-19, as well as 32 healthy donors (HD) over the course of 16 months. 5 of the MGH patients tested negative by qRT-PCR for SARS-CoV-2 and were included as non-COVID-19 samples. No methods were applied to calculate statistical power. 22 COVID patients and 19 HD were included in the freshly isolated phenotypic analysis presented in Figure 1a-b. 12 COVID patients and 10 HD were included in the ex vivo characterization of Figure 1c-e. 68 COVID patients, 5 non-COVID-19 and 20 HD were included in the plasma analysis presented in Figure 1f,g. For all other phenotypic characterizations by imaging flow cytometry, flow cytometry and qRT-PCR (Figures 2 and 3, Extended data Figure 2 and 3), the sample size had a minimum of 4 HD, non-COVID-19 and COVID-19 subjects. The number of subjects examined depended on the number of subjects available at each collection day and their cell yield.</p> <p>The in vitro infection assays (Figure 4 and Extended Data Figure 4 and 5) were performed with a minimum of 3 healthy donors (on the same day) whose blood was collected at Brigham and Women's Hospital Blood Bank.</p> <p>In addition, plasma from a separate cohort of 60 COVID-19 patients presenting to the MGH ED AND 10 HD was included in Figure 1f. No methods were applied to calculate statistical power. Plasma was collected on day 0 (n=60) and also on days 3 (n=42) and 7 (n=35) if the patients were hospitalized.</p> <p>Lung autopsies from 5 COVID-19 deceased patients and 3 trauma-related patient were used to quantify virus-infected cells and ASC speck formation.</p>
Data exclusions	Previously vaccinated patients, who had breakthrough infections, were excluded from this manuscript to avoid confounding effects of vaccination on antibody-mediated infection. This was decided before the data analysis but not before sample collection.
Replication	Inflammasome detection experiments (Figure 2a-c) were performed at least 3 times with at least one HD and one COVID patient each time. The data presented combines all donors tested. In vitro infection assays (Figure 4 and Extended Data Figure 4 and 5) were performed at least 2 times with 3 donors at a time. No experimental data was excluded because of lack of reproducibility.
Randomization	The inclusion of patients in our study was completely random. Subjects were assigned as they arrived at the MGH ED if they agreed to consent. The Brigham and Women's Blood Bank provided random, unidentified healthy donor samples of materials that would have been discarded.
Blinding	All the data acquisition of plasma samples and flow cytometry and imaging flow cytometry acquisitions were performed blinded as to their SARS-CoV-2 infection status.

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

## Materials &amp; experimental systems

## Methods

n/a	Involved in the study
<input type="checkbox"/>	<input checked="" type="checkbox"/> Antibodies
<input type="checkbox"/>	<input checked="" type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input checked="" type="checkbox"/>	<input type="checkbox"/> Animals and other organisms
<input type="checkbox"/>	<input checked="" type="checkbox"/> Human research participants
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input type="checkbox"/>	<input checked="" type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging

## Antibodies

## Antibodies used

Reagent or Resource Source Identifier (clone, Cat. #)

## Antibodies

## Flow Cytometry Dilution

Mouse anti-human PerCP-Cy5.5 CD4 BioLegend Clone SK3; Cat. # 344608 1:200

Mouse anti-human PE-Cy7 CD14 BioLegend Clone HCD14; Cat. # 325618 1:200

Mouse anti-human PE CD16 BioLegend Clone 3G8; Cat. # 302008 1:200

Mouse anti-human APC CD16 BD Biosciences Clone B73.1; Cat. # 561304 1:200

Mouse anti-human PE-CF594 CD16 BD Biosciences Clone 3G8; Cat. # 562320 1:200

Mouse anti-human AlexaFluor 488 CD19 BioLegend Clone SJ25C1; Cat. # 363038 1:200

Mouse anti-human APC-Cy7 CD19 BioLegend Clone SJ25C1; Cat. # 363010 1:200

Mouse anti-human Brilliant Violet 650 CD19 BioLegend Clone HIB19; Cat. # 302237 1:100

Mouse anti-human APC-Cy7 CD8 BioLegend Clone SK1; Cat. # 344714 1:200

Mouse anti-human Brilliant Violet 421 CD3 BioLegend Clone UCHT1; Cat. # 300434 1:200

Mouse anti-human APC-Cy7 CD3 BioLegend Clone UCHT1; Cat. # 300426 1:200

Mouse anti-human APC-Cy7 CD56 BioLegend Clone HCD56; Cat. # 318332 1:100

Mouse anti-human Brilliant UltraViolet 737 CD56 BD Biosciences Clone NCAM16.2; Cat. # 349105 1:200

Mouse anti-human AlexaFluor 488 HLA-DR BioLegend Clone G46-6; Cat.# 307620 1:200

Mouse anti-human Brilliant UltraViolet 395 HLA-DR BD Biosciences Clone G46-6; Cat. # 564040 1:200

Mouse anti-human PerCP-Cy5.5 CD123 BD Biosciences Clone 7G3; Cat. # 558714 1:100

Mouse anti-human Brilliant Violet 421 CD11c BD Biosciences Clone B-LY6; Cat. # 562561 1:200

Mouse anti-human purified CD32 StemCell Technologies Clone IV.3; Cat. # 60012 1:100

Goat anti-human/mouse/rat/hamster purified ACE2 R&D Systems Polyclonal; Cat # AF933 1:100

Normal Goat IgG Control R&D Systems Polyclonal; Cat # AB108C 1:100

Mouse anti-human APC CD147 BioLegend Clone HIM6; Cat # 306214 1:100

## Imaging Flow Cytometry, Immunofluorescence and Western blot

Mouse anti-dsRNA SCICONS Clone J2; Cat. # 1001020 1:500

Rabbit purified anti-SARS-CoV-2 Nucleocapsid GeneTex Polyclonal; Cat. # GTX135357 1:500

Mouse anti-human ASC Sigma Clone 2EI-7; Cat. # 04-147 1:200

Rabbit anti-human ASC Santa Cruz Polyclonal; Cat. # sc-22514-R 1:200

Goat anti-human NLRP3 Abcam Polyclonal; Cat. # ab4207 1:200

Mouse anti-human AIM2 Abcam Clone 3C4G11; Cat. # ab204995 1:200

Rabbit anti-human MEFV (Pyrin) Proteintech Polyclonal; Cat. # 24280-1-AP 1:200

Mouse anti-human GSDMD Lieberman lab Hybridoma (ref 55) 1:200

Rabbit anti-human GSDMD C-terminal Abcam Clone EPR19829; Cat. # ab210070 1:1000

Rabbit anti-human COX-IV Cell Signaling Clone 3E11; Cat. # 4850S 1:1000

Mouse anti-b-actin DSHB Polyclonal; Cat. # JLA-20 1:1000

Rabbit anti-SARS Nucleocapsid Novus Polyclonal; Cat. # NB100-56576 1:500

Rabbit anti-human CD14 Cell Signaling Clone D7A2T; Cat. # 75181 1:100

Rabbit anti-human CD31 Abcam Polyclonal; Cat. # ab28364 1:100

Mouse anti-human E-cadherin Santa Cruz Clone G-10; Cat. # sc-8426 1:100

Mouse anti-human ASC Santa Cruz Clone B-3; Cat. # sc-514414 1:100

Donkey anti-Rabbit IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 488 ThermoFisher Polyclonal; Cat. # A-21206 1:1000

Donkey anti-Rabbit IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 647 ThermoFisher Polyclonal; Cat. # A-31573 1:1000

Donkey anti-Mouse IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 647 ThermoFisher Polyclonal; Cat. # A-31571 1:1000

Donkey anti-Mouse IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 488 ThermoFisher Polyclonal; Cat. # A-21202 1:1000

Donkey anti-Goat IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 568 ThermoFisher Polyclonal; Cat. # A-11057 1:1000

Donkey anti-Goat IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 488 ThermoFisher Polyclonal; Cat. # A-11055 1:1000

Donkey anti-Goat IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 647 ThermoFisher Polyclonal; Cat. # A-21447 1:1000

Amersham ECL Mouse IgG, HRP-linked whole Ab (from sheep) Cytiva Life sciences Polyclonal; Cat. # NA931-1ML 1:5000

Amersham ECL Rabbit IgG, HRP-linked whole Ab (from donkey) Cytiva Life sciences Polyclonal; Cat. # NA934-1ML 1:5000

Alexa Fluor 488 Tyramide ThermoFisher Cat. #B40953

Alexa Fluor 555 Tyramide ThermoFisher Cat. #B40955

Alexa Fluor 594 Tyramide ThermoFisher Cat. #B40957

Alexa Fluor 647 Tyramide ThermoFisher Cat. #B40958



## Functional Assays

Human IgG1 Johnatan Abraham, Harvard Medical School Clone mAb114 10 µg/ml  
 Human anti-SARS-CoV-2 Spike protein, neutralizing Johnatan Abraham, Harvard Medical School Clone C1A-B12 10 µg/ml  
 Human anti-SARS-CoV-2 Spike protein, non-neutralizing Johnatan Abraham, Harvard Medical School Clone C1A-H12 10 µg/ml  
 Ultra-LEAF Purified anti-human CD16 Antibody BioLegend Clone 3G8; Cat. # 302050 10 µg/ml  
 Anti-human CD32 Monoclonal Antibody StemCell Technologies Clone IV.3; Cat. # 60012 10 µg/ml  
 Anti-human CD32 Monoclonal Antibody ThermoFisher Clone 6C4; Cat. # 16-0329-81 10 µg/ml  
 Ultra-LEAF Purified anti-human CD64 Antibody BioLegend Clone 10.1; Cat. # 305048 10 µg/ml  
 Ultra-LEAF Purified Mouse IgG1, κ Isotype Ctrl Antibody BioLegend Clone MOPC-21; Cat. # 400165 5-40 µg/ml  
 Goat anti-human/mouse/rat/hamster purified ACE2 R&D systems Polyclonal; Cat. # AF933 10 µg/ml  
 Normal Goat IgG Control R&D Systems Polyclonal; Cat. # AB108C 10 µg/ml  
 Ultra-LEAF Purified anti-human CD147 Antibody BioLegend Clone HIM6; Cat. # 306221 10 µg/ml

## Validation

Each antibody and dye was validated following the manufacturer's instructions or based on previously published methods. The antibodies and dyes were titrated to obtain the optimal concentration for use in our panels. All primary antibodies were human-specific. The secondary antibody host species was chosen according to the primary antibody. The antibody specificity was compared to isotype control where applicable.

## Eukaryotic cell lines

### Policy information about [cell lines](#)

Cell line source(s)	THP-1 (ATCC), Vero-E6 (ATCC), HEK293T and A549 overexpressing ACE2 (HEK293T and A549 parental cell line was from ATCC and was lentivirally transduced with ACE2 gene in Anne Goldfeld's lab (Boston Children's Hospital)).
Authentication	Cells were low passage cells from ATCC, which authenticates them. Cell morphology and growth was consistent with THP-1, and the cells showed signs of inflammasome activation once stimulated with the right reagents. ACE2 overexpression in HEK293T and A549 cells was confirmed by flow cytometry.
Mycoplasma contamination	Cells were frequently tested for mycoplasma contamination and were negative.
Commonly misidentified lines (See <a href="#">ICLAC</a> register)	None

## Human research participants

### Policy information about [studies involving human research participants](#)

Population characteristics	<p>The fresh PBMC cohort were patients who enrolled in the MGH ED from 7/9/20 to 10/15/21. These included male and female patients 18 years or older (range 26-82) with clinical symptoms suggestive of COVID-19 infection (including one or more of the following: sore throat, congestion, cough, anosmia, shortness of breath, hypoxia, chest pain, fever, gastrointestinal symptoms, abdominal pain, nausea or vomiting and diarrhea). All patients testing positive by qRT-PCR for SARS-CoV-2 were included in the study, independently of race, ethnicity, BMI (range 18.00-47.81), co-morbidities, or whether they were receiving immunosuppressive treatment (3 patients). Blood was collected on the same day as the swab collection for PCR test. Clinical course was followed for 7 d post-enrollment or until hospital discharge, if that occurred after 7 d. Patients were assigned a maximum acuity score (A1-A5) based on their worst illness severity over 7 days (A1 – died (n=0), A2 – required mechanical ventilation (n=5), A3 – hospitalized requiring supplemental oxygen (n=18), A4 – hospitalized not requiring supplemental oxygen (n=4), A5 – discharged and not requiring subsequent hospitalization (n=4)).</p> <p>The frozen plasma cohort included 60 patients who enrolled in the MGH ED from 3/15/20 to 4/15/20. These included patients 18 yr or older (range 20-80+) with clinical symptoms suggestive of COVID-19 infection and at least one of the following: (i) tachypnea <math>\geq 22</math> breaths per minute, (ii) oxygen saturation <math>\leq 92\%</math> on room air, (iii) requirement for supplemental oxygen, or (iv) positive-pressure ventilation. All patients testing positive by qRT-PCR for SARS-CoV-2 were included in the study, independently of race, ethnicity, BMI or co-morbidities. Blood was obtained at presentation, on the same day as the swab collection for PCR test (n=60) and on days 3 (n=42) and 7 (n=35) if the patient was hospitalized on those dates. Clinical course was followed for 28 d post-enrollment or until hospital discharge if after 28 d. SARS-CoV-2-confirmed patients (by qRT-PCR) were assigned a maximum acuity score (A1-A5) based on their worst illness severity over 28 d and were divided into three groups for comparison– severe (A1 – died, A2 – required mechanical ventilation, n=32), moderate (A3 – hospitalized requiring supplemental oxygen, n=16), and mild (A4 – hospitalized not requiring supplemental oxygen, A5 – discharged and not requiring subsequent hospitalization, n=12).</p> <p>Lung autopsies cohort included 5 COVID-19 deceased patients and 3 trauma-related deceased patient and without lung disease. Lung specimens were obtained within 24 h of autopsy from Massachusetts General Hospital (MGH).</p> <p>Anonymous healthy donor blood samples were obtained from the blood bank at Brigham and Women's Hospital in Boston, USA.</p>
Recruitment	The fresh PBMC cohort was recruited by study coordinators from patients 18 years or older who were enrolled in the MGH ED from 7/9/20 to 10/15/21 with clinical symptoms suggestive of COVID-19 infection. All recruited patients provided signed informed consent. A 10-ml EDTA blood sample was transported to Boston Children's Hospital and processed within 2 h of collection. Only patients testing positive by qRT-PCR for SARS-CoV-2 were included in the study. The MGH COVID-19

Collection & Processing Team was in charge of recruitment.

The frozen plasma cohort included 60 patients that were enrolled in the MGH ED from 3/15/20 to 4/15/20 with an IRB-approved waiver of informed consent. These included patients 18 yr or older (range 20-80+) with clinical symptoms suggestive of COVID-19 infection and at least one of the following: (i) tachypnea  $\geq 22$  breaths per minute, (ii) oxygen saturation  $\leq 92\%$  on room air, (iii) requirement for supplemental oxygen, or (iv) positive-pressure ventilation. All patients testing positive by qRT-PCR for SARS-CoV-2 were included in the study. A 10-ml EDTA tube was obtained with the initial clinical blood draw in the ED (n=60) and on days 3 (n=42) and 7 (n=35) if the patient was hospitalized on those dates. Clinical course was followed for 28 d post-enrollment or until hospital discharge if after 28 d. The MGH COVID-19 Collection & Processing Team was in charge of recruitment.

Lung samples from 5 deceased individuals were obtained from Massachusetts General Hospital (MGH). Informed consent was obtained from relatives of study participants.

Anonymous healthy donor blood samples were obtained from the blood bank at Brigham and Women's Hospital in Boston, USA.

#### Ethics oversight

Boston Children's Hospital and Massachusetts General Hospital Internal Review Boards

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Flow Cytometry

### Plots

Confirm that:

- The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- All plots are contour plots with outliers or pseudocolor plots.
- A numerical value for number of cells or percentage (with statistics) is provided.

### Methodology

#### Sample preparation

COVID-19 and HD samples were processed using recommended safety precautions in a BSL-2+ facility. PBMC were purified using Ficoll gradient centrifugation and subjected to red blood cell lysis (if necessary) with Red Blood Cell Lysing Buffer Hybri-Max. One fraction of PBMC was stained for flow cytometry, while the remaining cells were used for monocyte or neutrophil purification by negative selection using magnetic beads. Purity was always greater than 95%.

PBMC were washed and stained for viability with Zombie Yellow in PBS (1:200) for 15 min on ice. Cells were washed with PBS, centrifuged, and then stained with Annexin V PE (1:200) in 1x Annexin Buffer for 15 min on ice. After washing with 1x Annexin V buffer, cells were blocked for 10 min with anti-CD32 (1:100) in PBS + 3% FBS. PBMC were then stained for 15 min on ice with a cocktail of antibodies to identify lymphocyte and myeloid cell subsets (all 1:200 except CD19 BV650, CD123 PerCP-Cy5.5 and CD56 APC-Cy7, 1:100). Purified monocytes were blocked with anti-CD32 and then stained with purified ACE2 antibody (1:100) for 15 min. The secondary anti-goat AF488 (1:1000) was coincubated with CD14 PE-Cy7 (1:200) and CD147 APC (1:100). After a last wash, PBMC or monocytes were resuspended in 2% PFA and kept at 4°C until flow cytometry analysis.

Monocytes purified from HD PBMC using negative selection magnetic beads were cultured overnight in RPMI + 10% human AB serum and 1% Penicillin/Streptomycin with 100 ng/ml LPS. Monocytes or fresh isolated neutrophils were infected with icSARS-CoV-2-mNG (a molecular clone of SARS-CoV-2 expressing Neon Green fluorescent protein) using an MOI of 1 in a BSL-3 facility. The inoculum was treated with 10% COVID-19 patient pooled plasma (that had been depleted or not of IgG using Protein A/G agarose beads) before infection for 30 min at room temperature. 100 microliters of treated virus were added to monocytes ( $2 \times 10^6$  cells/well) in 48 well plates. Infected cells were incubated at 37°C, 5% CO<sub>2</sub> with gentle shaking every 10 min for 1 h, after which the culture volume was increased to 0.5 ml with RPMI supplemented with 5% heat inactivated normal AB human serum and 10% COVID-19 patient plasma (treated as described). Cultures were then incubated at 37°C, 5% CO<sub>2</sub> for 48 h at which time cells were harvested and fixed for 20 min with 4% PFA. Monocytes were then permeabilized with 0.1% Triton X-100, then blocked with PBS + 5% FBS. Cells were stained with primary antibodies for nucleocapsid (rabbit 1:500) then stained with secondary antibody (donkey anti-rabbit conjugated with AlexaFluor 647, at 1:1000) and anti-CD14 PE-Cy7.

#### Instrument

BD FACS Canto II and BD LSR II

#### Software

Flow cytometry data were acquired with FACSDiva (BD)  
Flow cytometry data were analyzed with FlowJo v 10.7.1 (BD)  
Graph design and statistical analysis were performed with GraphPad Prism V9.0.

#### Cell population abundance

All PBMC, all CD14+ monocytes or all neutrophils

#### Gating strategy

1. PBMC and monocyte populations were identified by FSC-A/SSC-A.
2. PBMC and monocytes were gated as singlets by FSC-H/FSC-W.

3. For assessment of cell death within PBMC (Figure 1a-c), specific cell populations were gated as shown in Extended Data Figure 1, and then Zombie/Annexin V percentages were analyzed.
4. For assessment of ACE2 and CD147 in HD and COVID-19 monocytes (Extended Data Figure 3) and J2/NeonGreen in SARS-CoV-2-infected HD monocytes (Figure 4, cells were gated in SSC-A/CD14+.

Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.